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ABSTRACT
   Iridoviruses are considered infectious pathogens that are responsible for causing
serious systemic diseases among aquatic animals in many parts of the world. In fish,
outbreaks of an iridoviral disease known as red seabream iridoviral disease (RSIVD)
have been recorded in at least 31 cultured marine fish species. The causative pathogen
was first isolated from diseased red seabream (Pagrus may'or) in Japan in 1992 and hence
named red seabream iridovirus (RSIV). Due to the devastating effects ofthis pathogen to
marine aquaculture, the pathogenic mechanism ofRSIV infection has been well-studied
at the organismal level. Some rapid, sensitive diagnostic methods as well as some kinds
of vaccines have also been developed for RSIV. RSIV gene regulation strategies that
occur in a common temporal kinetic manner of the family Jridoviridae with 3 stages
(Immediate-Early, Early and Late) have been well-defined in a cell culture system.
However, the molecular pathogenic mechanism or the spread ofRSIV in a fish model at
the molecular ievel is still not fully understood. The development of alternative antiviral
approaches based on advances in molecular technology may also need to be undertaken.
Such studies will be of enormous contribution to the thorough knowledge of RSIV
infection and control ofiridoviral diseases.
   Recent significant advances in molecular genetic technology, such as DNA
microarray and RNA interference (RNAi), have been successfu11y appiied in virological
studies. The DNA microarray technology has been considered as a powerful tool for the
parallel analysis of whole-genome expression levels in a single experiment, allowing a
better understaRding of viral gene regulation strategies and viral molecular pathogenic
mechanisms. While the RNAi technology, a process of sequence-specific gene silencing
triggered by small molecules ofdouble-stranded RNAs (siRNAs and miRNAs), has been
considered as a promising antiviral tool. The antiviral potency of RNAi can be evoked by
the introduction of viral gene-specific siRNAs or plasmid-based virus-encoded hairpin
RNA expression system into cells. In this study, therefore, we demonstrated the
molecular pathogenic mechanism of RSIV infection in a fish model using viral DNA
Xi
microarrays and the potential antiviral activity of RSIV-derived dsRNAs through the
introduction of viral gene-specific siRNAs and plasmid expressing virus-encoded pre-
miRNAs into a cell culture system.
   The transcriptional profile of RSIV was explored over the time-course of the virus
infection in infected spleen of red seabream using viral DNA microarrays containing
almost all RSIV putative open reading frames (ORFs). cDNAs derived from spleens at
different time points upto 14 days post-infection (d.p.i.) were labeled with cy5 and
hybridized with cDNAs derived from spleens at O d.p,i. that were labeled with cy3 onto
the DNA microarrays. In addition, differential gene expression patterns in spleens and
kidneys were also investigated throughout the virus infection by hybridization of cy5-
labled-cDNAs derived from spleens with cy3-labeled-cDNAs derived from kidneys.
Microarray data indicated that the pathogenesis of RSIV infection appears to spread at
around day 5 and continued with high Ievels of viral multiplication until viral clearance
by host antiviral defenses starting from around 10 d.p.i. A comparison of RSIV gene
expression patterns between spleens and kidneys showed that all viral genes were
expressed at higher levels or at similar levels in the spleens when compared with those in
the kidneys throughout the infection. The infectious viral concentration in infected
spleens, as measured by TCIDso assay, was also higher than that in infected kidneys. The
microarray data was further confirmed by RT-PCR assay. Our results provided a greater
understanding of the pathogenesis of RSIV infection and further confirmed, at the
molecular level, that the spleeR is a suitable organ for diagnosis ofRSIV infection.
   Major capsid protein (MCP) gene ofRSIV, a gene essential for the formation ofviral
particles, was selected as the target gene for study ofthe potential anti-RSIV option based
RNAi-related mechanisms. A siRNA specific to the MCP gene (siR-MCP) were
synthesized and introduced into HINAE cells in order to test for inhibitory effects on
virus replication. The inhibition of virus replication was demonstrated by reduced MCP
expression levels and reduced RSIV titers. siR-MCP dose-dependently inhibited the
expression of MCP gene in cells that were transiently transfected or stably transfected
with a plasmid expressing the target MCP gene (pCMV-MCP). Under RSIV infection,
siR-MCP reduced the expression of MCP gene by 55.20/o and 97.10/o at 84 and 96 hours
Xii
post-infection, respectively. Transfection with siR-MCP reduced the production ofRSIV
particles in supernatants of samples infected with RSIV, while the corresponding
mismatched siR-MCP (MsiR-MCP) and nsRNA controls did not exhibit this effect.
These results show that MCP-targeted siRNA can effectively and specifically inhibit the
expression ofthe target gene and hinder RSIV replication during an in vitro infection.
   With the use ofplasmid-based pre-miRNA expression system (Block-iT'M Pol II miR
RNAi Expression Vector), we described another potential approach to trigger antiviral
RNAi, termed microRNAs (miRNAs). In this miRNA study, another marine fish-
pathogenic virus, HIRRV (Hirame rhabdovirus) also was an interesting candidate. By
incorporating sequences encoding miRNAs specific to MCP gene (miR-MCPs) and a
miRNA targeting to HIRRV (miR-HIRRV) into a murine miR-155 pre-miRNA backboRe,
we were able to intracellularly express miR-MCPs and miR-HIRRV in HINAE cells. The
anti-RSIV activity of miR-MCPs was initially assessed by measuring MCP gene
silencing by employing transient transfection of a plasmid expressing the target gene
(pCMV-MCP). We then investigated the inhibitory effect of the miR-MCPs on RSIV
replication following challenge with RSIV. The inhibitory effect of miR-HIRRV on
HIRRV replication was demonstrated by reduced expression of viral glycoprotein (G)
gene and reduced HIRRV titers in plasmid-transfected cells over the time-course of the
virus infection. Our results suggested that engineered viral-encoded miRNAs were able to
trigger the antiviral miRNA•-related pathways in fish cells. However, further analyses
revealed that the expression of pre-miRNAs also activated IFN-related pathways,
correlating with the up-regulation of antiviral IFN-induced Mx protein, resulting in non-
specific antiviral effects. The antiviral effects of engineered virus-encoded miRNAs
observed here were partly the result ofthe antiviral miRNA-related pathways and partly
the result of the antiviral IFN-related pathways. We propose that engineered virus-
encoded pre-miRNA can engage not only RNAi-related pathways but also IFN-related
pathways to induce potent antiviral responses in fish cells.
   Also in this study, some general discussions, suggestions and future perspectives
                                            'were included.
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    CHAPTER 1
GENERAL INTRODUCTION
1
1.1 Overview
   Over the past three decades, aquaculture has become the fastest growing food-
producing sector all over the world. As the aquaculture industry has expanded, intensified
and diversified, numerous aquatic animal diseases have emerged and become widespread
as a result of global trade and modern transportation systems. Diseases caused by viruses,
bacteria, fungi, parasites and other undiagnosed pathogens have thus become a primary
constraint to the culture of many aquatic species, impeding both economic and social
development in many countries. Among these pathogens, viruses pose the most serious
threat to fish because they affect almost all phases of its developmental stages (Ellis,
2001).
   Viral infections that occur as sporadic events in wild fish populations may cause high
mortality in intensive aquaculture systems. Hence, for the aquaculture industry to prosper
and be sustainable, it is imperative that losses caused by viral diseases and the use of
antimicrobials are kept at the minimum. Unlike other pathogens, viruses are very small
pathogens that multiply only within the living cells, and must utilize the system of the
infected host cells for survival and replication, therefore, viral diseases cannot be
controlled with medication. Although innate immune system is the first line of defense
against disease, this system only provides adequate protection in conditions of low
infection pressures from pathogens, and indeed, dead fish release very large numbers of
pathogens into the water, increasing infection pressure, resulting in increased ri'sk for the
rest ofthe population in a farm (Ellis, 2001). Moreover, most pathogens have developed
mechanisms for avoiding these defenses. Many RNA and DNA viruses counteract the
host antiviral immune defenses through mutation of their genome, by encoding viral
suppressors, or both (Zheng et al., 2005). In these cases, antiviral immunity responses
need to be enhanced to combat viral infections. Despite significant advances made in
management of environment and control of viral diseases, current biochemiCal agents and
vaccines are limited by many factors, such as toxicity, complexity, cost and resistance
(Dave and Pomerantz, 2003). For instance, virus-inactivated vaccines show poor
induction of cell-mediated immunity, poor immunogenicity and the increased risk of
environmental exposure to viral products (Caipang et al., 2006). Moreover, though
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vaccination is used routinely to prevent viral diseases in humans and mammals, it is still
limited in fish because fish are cold-blooded animals, and their immune response to a
vaccine is not as predictable as that of warm-blooded animals. Thus, understanding the
molecular pathogenic mechanisms of viral infections in fish will be of enormous help in
the proper management and prevention of viral diseases. The development of alternative
potential approaches that are experimentally exploited based on relatively antiviral
pathways in fish to control viral infections will eventually lead aquaculture towards
sustainable production in the aquatic ecosystem. Recent potential advances in molecular
genetic technologies, such as DNA microarray and RNA interference (RNAi) could be
applied in these directions.
   The DNA microarray technology has been considered as a powerfu1 tool for the
parallel analysis of whole-genome expression levels in a single experiment and for the
comparative analysis of series of samples. The design and construction of a DNA
microarray for any given microbial genome are straightforward, facilitating our
understanding of various aspects of both sides of the host-pathogen interaction in
molecular detail (Cummings and Relman, 2000). While RNAi technology, a process of
gene sequence-specific silencing triggered by small molecules of double-stranded RNA
(dsRNAs), has been considered as a promising antiviral tool. RNAi-related mechanisms
can also be triggered by experimentally introduced synthesis dsRNAs into cells in various
ways allowing to target any gene with high specificity and efficiency based on homology
in sequences (Schutze, 2004; Sledz and Williams, 2005; van Rij and Andino, 2006;
Zheng et al., 2005).
1.2 Major infectious viral diseases in fish aquacu}ture
   Although about 60 different viruses have been detected in fish worldwide, only a few
cause severe diseases in aquaculture (dne, 1994). The causative agents Qf major viral
diseases in fish worldwide are briefly updated in Table 1. Among the diseases caused by
these viruses, epizootic haematopoietic necrosis, infectious haematopoietic necrosis,
spring viremia of carp, viral haemorrhagic septicemia, infectious salmon anaemia, red
seabream iridoviral disease, and koi herpesvirus disease are recently listed as "notified"
viral diseases by Office International des Epizooties (OIE) because they are considered to
3
Table 1. The causative agents of major viral diseases in fish
Viruses Distribution of d .Iseases
                              Jridoviridae
Epizootic haematopoietic necrosis virus (EHNV)
Erythrocytic necrosis virus (ENV)
Lymphocystisvirus (LCV)
Red seabream iridovirus
White sturgeon iridovirus
Australia, Europe, North America
Worldwide
Worldwide
Japan, East and South-East Asian
Europe, North America
Anguilla herpesvirus
Carmel catfish virus (CCV)
Coho salmontumorvirus
Flounder herpesvirus
Herpesvirus salmonis
Koi herpesvirus (KHV)
Oncorhychus masou virus (OMV)
Herpesviridae
Japan
North America
Japan
Japan
USA
Worldwide
Japan
                            Rhabdoviridae
Anguilla rhabdovirus (EVA, EVX)
Hirame rhabdovirus
Infectious hematopoietic necrosis virus (IHNV)
Pike fry rhabdovirus
Spring viremia of carp virus (SVCV)
Ulcerative disease rhabdovirus
Viral hemorrhagic septicemia virus (VHSV)
Japan, Europe
Japan
Asia, USA, Europe
Europe
Europe
Burma, Sri Ianka, Thailand
Japan, USA, Europe
                             BirnaviTi
Infectious pancreatic necrosis virus (IPNV)
dae
Worldwide
                             No daviridae
Viral encephalopathy and retinopathy (VER) or
Viral nervous necrosis (VNN)
Worldwide
                           Orthomyxoviridae
Infectious salmon anaemia virus (ISAV) Norway, Canada, UK, USA
Reoviridae
Grass carp reovirus
Reovirus ofcommon carp
Reovirus of salmonids
China
China
Taiwan
Coronaviridae
Coronavirus of carp Japan
4
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1.3 Viral diseases ofmarine fish in Japan
   The intensification of aquaculture in both the number of species and the amount of
production without proper regulations for disease control is considered to be the major
factor for the failure of establishing a disease control system in Japan. The viruses
infecting marine fish and shellfish were comprehensively discussed by Muroga (2001)
(Muroga, 2001). Yellowtail ascites virus (YTAV) isolated from juvenile yellowtail in
1983 was reported as the first marine fish-pathogenic virus in marine aquaculture
(Sorimachi, 1985). Since then, several viral diseases have been recorded from marine
fish. There have been cases of rhabdoviral diseases that was caused by Hirame
rhabdovirus (HRV) (Kimura, 1986) or viral hemorrhagic septicemia (VHSV) (Isshiki,
2001; Takano, 2000), and red seabream iridoviral disease that was caused by red
seabream iridovirus (RSIV) (Inouye et al., 1992). Other viruses include fiounder
herpesvirus (FHV) which causes epidermal hyperplasia in Japanese flounder, tiger puffer
virus which causes "white mouth disease" in puffer fish (Wada, 1986), epithelial necrosis
virus identified in black seabream (Miyazaki, 1989), and viral nervous necrosis (VNN)
that was first identified in Japanese parrotfish (Yoshikoshi, 1990) and has since infected
several other marine fish (Nguyen, 1994). These viruses are considered to be important
pathogens in marine aquaculture in Japan.
   Concerning red seabream iridoviral disease (RSIVD), .it is reported as an acute and
highly infectious disease that causes a significant mortality in red seabream (Inouye et al.,
1992) and 30 other cultured marine fish spanning three taxonomic orders (Table 2)
(Kawakami and Nakajima, 2002). The first outbreak of RSIVD was recorded in cultured
red seabream in Shikoku Island in 1990 and the disease has since been documented in
cultured marine fish populations in 18 prefectures in the country. The disease was
severely apparent during the summer time when the water temperature is elevated around
250C. The pathological signs were lethargy, severe anemia, petechiae of gills, and
enlargement of spleen and kidney. The disease is characterized by the appearance of
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enlarged cells in the spleen, kidney, liver, heart, and gills that were stained strongly with
Giemsa solution. The causative agent was identified and narned red seabream iridovirus
(RSIV) (Inouye et al., 1992). Iridovirus-like agents of the family Jridoviridae are
observed in both invertebrates and vertebrates (Hedrick, 1992), and most of them are
confirmed to be pathogens that are associated with systemic infection in fish (Wolf,
1988). Because of geographical range and occurrence in fish involved in international
trade, the RSIVD is notified to be quarantined by the OIE.
Table 2. Fish species susceptible to RSIV infection in Japan
Sea bass (Lateolabrax sp)
Red spotted grouper (Epinephelus akaara)
Sevenband grouper (E. Septemfasciatus)
Malabar grouper (E. malabaricus)
Kelp grouper (E. Moara)
Orange-spotted grouper (E. coioides)
Banded grouper (E. AwoaTa)
Cobia (RachycentTon canadum)
Yellowtail (Seriola guingueradiata)
Amberjack (S. dumeTili)
Goldstriped amberjack (S. aureoittata)
Stripedjack (Pseudocaranx dentex)
Buri-hira (Seriola sp.)
Horse mackerel (TrachurusJ'aponicus)
Percopormes (28 species)
         Snubnose dart (Trachinotus bloch
                         ii)
Threeline grunt (Parapristi oma trilineatum)
Threeband sweetlips (Plectorhynchus cinclus)
Adjutant (Lethrinus haematopterus)
Spangled emperor (L. nebulosus)
Red seabream (Pagrus mojor)
Crimson seabream (Evynnisl'aponica)
Black seabream (Acanthopagrus schlegeli)
Japanese parrot fish (Oplegnathusfasciatus)
Spotted parrot fish (O. punctatus)
Largescale blackfish (Girellapunctata)
Albacore (Thunnus thynnus)
Japanese mackerel (Scomberomorus ni honius)
Chub mackerel (Scomberl'aponicus)
Japanese flounder (Paral
     Pleuroneetopormes (2 species)
ichthys olivaceus) Spotted halibut (Verasper variegates)
Tiger puffer (Takifugu rubrip
 Tetraodontiformes (1 species)
es)
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1.4 Red seabream iridovirus: characteristic, diagnosis and control
   RSIV is a large, icosahedral, double-stranded (ds)DNA virus, belonging to the family
lridoviridae. Each virion measures 200-240 um in diameter and consisted of a capsid,
intermediate lipid membrane and a central core (Inouye et al., 1992). RSIV is believed to
have a wide geographical distribution not only in Japan but also in other East and South-
East Asian countries (Jeong et al., 2003; Mahardika et al., 2004; Wang et al., 2003),
and shares high homology with iridovirus isolated in Taiwan (Wang et al., 2003), Korea
(Jeong et al., 2003) and in Indonesia (Mahardika et al., 2004). The high homology ofthe
RSIV ATPase and MCP genes with other iridovirus isolates, SBIV (Sea bass iridovirus),
GSDIV (Grouper sleepy disease virus), ALIV (African lampeye virus) and DGIV (Dwarf
gourami iridovirus) led to a proposal to name a new genus for this group in the
lridoviridae family known as "Tropivirus" (Sudthongkong et al., 2002).
   Studies on the biological and physicochemical characteristics showed that RSIV
produced cytopathic effect (CPE) in several fish cell lines at suitable temperature from
20-250C; sensitive to low pH (3), chloroform and ether; unstable to heat treatment but
stable to ultrasonic treatment. However, the virus titers were reduced by repeated freezing
and thawing (Nakajima and Sorimachi, 1994). RSIV induced apoptosis in vitro and is
dependent on the presence ofcaspases (Imajoh et al., 2004). The cell apoptosis by RSIV
consisted ofthree stages: cell shrinkage and rounding at the early stage; cell enlargement
at the middle stage; formation of apoptotic body-like vesicles at the late stage and
phagocytosis by neighboring cells. Caspase-3 and caspase-6 involved in the
morphological changes during the mid- and late apoptotic stages and in viral protein
synthesis in the later stage of the virus infection.
   The complete genome sequences of RSIV is 1 12, 414 bp containing about 93 putative
open reading frames (ORFs) with a main structural component, the major c.apsid protein
(MCP) gene (Kurita et al., 2002). The MCP gene normally occupies upto 450/o oftotal
virion protein and is highly conserved among the family lridoviridae (Williams, 1996).
The MCP gene of RSIV has been confirmed to be the most suitable gene for detection
and measurement of the virus infection (Caipang et al., 2003). Several ORFs have been
assigned putative function based on significant matches with the potential proteins of
7
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Fig. 1. Distribution of IE, E and L transcripts in the RSIV genome and correlation with
genomic sequence data, Transcriptionally active regions are shown in black, while inactive or
undetected regions are showB in white. The irmermost circle indicates map units (m.u.) and kilobases (kb)
from map unit O. (A) Distribution oflE transcripts in the RSIV genome. (B) Distribution ofE transcripts in
the RSIV genome. The inner solid circle shows regions of E transcripts. The outer soiid-circle indicates
major clusters ofE transcripts. (C) Distribution ofL transcripts in the RSIV genome. The inner solid circle
shows regions of L transcripts. The outer solid circle indicates major clusters of L transcripts. (D)
Distribution of E and L exciusive regions in the RSIV genome. The three inner solid circles show major
clusters of IE, E, and L transcription in the innermost, middle, and outermost circles, respectively. The
outer solid circle indicates three regions exclusive to E transcripts encoding enzymes associated with viral
DNA replication and an L region contaming MCP. (Adapted from Lua et al. (Lua et al., 2005)).
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LCDV-1 (lymphocystis disease virus 1), RBIV and other better-studied viruses. These
proteins are those involved in DNA replication, DNA modification and processing, DNA
transcription, processing of viral DNA, protein processing and modification and virus-
host interaction. There are also other sequences in the genome that are considered RSIV-
specific genes, the large submit of DNA-dependent RNA polymerase, DNA polymerase,
ATPase and putative ankyrin repeat containing protein genes.
   In vitro RSIV replication and gene regulation strategies have been well-studied using
DNA microarray technology. Individual RSIV ORI?s were characterized at the
transcriptional level and were also classified into temporal kinetic classes by their
dependence on de novo protein synthesis and viral DNA replication. The gene expression
ofRSIV occurred in a temporal kinetic cascade with 3 stages, which includes Immediate-
Early (IE), Early (E) and Late (L) transcripts, following a common feature of the family
Iridoviridae. The three classes of transcripts were distributed throughout the RSIV
genome; however, E transcripts were found to be clustered in at least 6 discrete regions
and L transcripts appeared to originate from 7 discrete regions (Fig. 1) (Lua et al,, 2005).
   Diagnosis of RSIV infection has been achieved through virological, histological and
molecular approaches. These diagnostic techniques include cell culture (Nakajima and
Sorimachi, 1994), Giemsa staining (Inouye et al., 1992), immuno-assay usl'ng a
monoclonal antibody (Nakajima, 1995), conventional PCR (Oshima et al., 1998; Oshima
et al., 1996), as well as some sensitive, rapid diagnostic techniques, such as quantitative
real-time PCR (Caipang et al., 2003) and the loop-mediated isothermal amplification
(LAMP) reaction (Caipang et al., 2004).
   Control of RSIV infection was made possible through vaccination using virus-
inactivated and DNA vaccines. The virus-inactivated vaccine was prepared by addition of
formalin to the RSIV-infected cell culture supernatant and cells (Nakajima, 1997), while
DNA vaccines were produced by construction of DNA plasmids encoding the MCP and
an ORF containing a transmembrane domain ofRSIV (Caipang et al., 2006). The RSIV-
inactivated vaccine has been found to be highly efficiept in protecting the vaccinated-fish
both at the laboratory-scale (Nakajima, 1997) and field trials (Nakajima, 1999) and is
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now commercially available. The RSIV-DNA vaccines have also been found to be able to
induce significant protection in fish against RSIV infection (Caipang et al., 2006).
1.5 DNA microarray technology (gene chip technology)
1.5.1 Baekground
DNA microarrays, a high-capacity system, was first described and used for quantitative
expression measurements ofmany genes in 1995 by Schena et al. (Schena et al., 1995).
The DNA microarrays are basically a miniature foim ofdot blot, but in a high-throughput
format spotting thousands of different target probes on a small solid surface, such as a
coated glass slide or nylon membrane. The target probes can be DNA, cDNA or
oligonucleotides of selected genes, and are used to determine complementary binding of
the unlmown sequences. Although several different types of DNA microarrays have been
developed based on their target probes, the key unifying principle of all DNA microarray
experiments is a labeled nucleic acid hybridization-based technique with high sensitivity
and specificity. Each experiment consists of five discrete steps (Sellheyer and Belbin,
2004): (1) fabrication of the DNA microarray, (2) preparation of the biological sample,
(3) hybridization of the labeled nucleic acid sample with the array, (4) signal detection
and data visualization, and (5) data processing and analysis (Fig. 2).
   It is widely believed that thousands of genes and their products in a given living
organism function in a complicated and orchestrated way that creates the mystery oflife.
The same genes are not active or expressed in every cell. Gene expression is a sensitive
indicator of cellular metabolism, disease state and toxicant exposure, and thus represents
a unique way of characterizing how cells and organisms adapt to changes in the external
environnient (Lettieri, 2006). The measurement of gene expression levels facilitates the
annotation of the molecular mechanisms underlying normal cellular processes as well as
the molecular basis for disease. Obtaining such global views at the molecular level was
impossible using conventional molecular biological techniques (Choudhuri, 2004;
Sellheyer and Belbin, 2004). Thus, DNA microarray technology is revolutionary because
it allows for the monitoring of the expressions of thousands of genes in a single
experiment, providing a platform to perform genome-wide expression analyses across
various biological models. This enormous power of microarrays has already made a
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remarkable impact on many fields of biological and biochemical research, including
cellular physiology, cancer biology, and pharmacology (Cummings and Relman, 2000). It
is an undeniable fact that the number of publications employing microarrays has
undergone exponential growth since its inception in 1995 by Schena et al (Schena et al.,
1995). Since that time, the publications increased from 239 in 2000 to 4099 in 2005 with
an accumulated total of 12,679 microarray papers (Ju et al., 2007).
   DNA microarray experiments have been widely used in both basic and applied
research ranging from viruses to humans in order to answer different research questions
related to gene expression, for instance in gene discovery, drug discovery, disease
diagnosis and toxicological research. D. tt•.A microai`ray technology has. focused ok
identification ofnew genes based on similarities in expression patterns with known genes.
Ultimately, these studies may greatly expand the size of existing gene families, reveal
new patterns of coordinated gene expression across gene families, uncover entirely new
categories of genes, and identify genes involved in the different developmental stages of
diseases. The technology has already focused on the field of drug discovery and
development by screening for changes in gene expression following exposure of cells to
drug treatments. Correlation of gene expression with drug activity may enhance the
armotation of molecular details of drug action, while correlation of transcription profiles
in untreated cells with drug response may reveal mechanisms for sensitivity and
resistance, providing information to synthesize more effective drug targets and reduce
their adverse side effects (Choudhuri, 2004). In addition, with the evolution ofmicroarray
technology, it can be possible to learn more about different diseases and further classify
the types of diseases on the basis of the pattems of gene activity in specific target cells.
Microarray technology has also been a valuable tool in toxicology research involving
both mammals and aquatic anlmals by measuring gene expression levels upon exposure
Åío toxicants (Jv; et a{., 2007; Lettieri, 2006; van I-Ial et al., 2000).
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Fig.2. Principle model of DNA microarray experiment
1.5.2 Application ofthe DNA microarray technology in virologicalstudies
   The concurrent development of DNA microarray technology and the complete
sequencing of a number of viral genomes are providing the opportunity to speed our
understanding of various aspects of both sides of the host-virus interaction at the
molecular level. By understanding the molecular details of this interaction, we can
identify virulence-associated genes, host-defense strategies and characterize the cues to
which they respond and mechanisms by which they are regulated. In fact, DNA
microarray technology has been widely applied in virological studies in both cell culture
systems and experimental animal models. By monitoring viral gene expression, one can
explore viral replication and gene regulation strategies, predict the molecular pathogenic
mechanisms, predict the functions of uncharacterized genes, identify genes involved in
viral pathogenesis, and test the effects of drugs or inhibitors. Similarly, by using host
gene microarrays, one can explore host response at the level of gene expression and
provide a molecular description ofthe events that follow the viral infection (Cummings
and Relman, 2000). Firstly, DNA microarrays have been successfu11y used to study the
transcriptional profiles of variety of viruses, including plant (Pasquini et al., 2007),
insect (Yamagishi et al., 2003), mammalian (Martinez-Guzman et al., 2003; Paulose-
Murphy et al., 2001; Stingley et al., 2000) and aquatic viruses (Lua et al., 2005; Marks
et al., 2005). Secondly, they have focused on the host's transcriptional profiles following
viral infections (Bigger et al., 2001; Cuadras et al., 2002; Jones and /trvin, 2003; Otsuka
                                                            'et al., 2003). Viruses used as models in DNA microarray technology-based studies are
summarized in Table 3.
   Basically, the DNA microarray technology has been applied to explore the
transcriptional profiles of viruses during an infection or under different conditions, such
as different replication stages, drug treatmentslinhibitors and toxicity. Transcription of
HCMV genome was measured during infection by using a microarray of 75-mer
oligonuleotides representing each of the 226 predicted HCMV ORFs (Chambers et al.,
1999). By blocking de novo viral protein synthesis and viral DNA replication, the authors
revealed a detailed classification of HCMV genes into' four temporal kinetic classes, and
also assigned many ORFs, for which expression data were not previously available, into
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Table 3. Viruses used as models in DNA microarray technology-based studies
Virus References
Autographa californica multiple
nuleopolyhedrovirus (AcMNPV)
Coxsackievirus B3
Echovirus 1 (EVI)
Hepatitis B and C viruses
Hepatitis C virus (HCV)
Herpes simplex virus type 1 (HSV-1)
Herpesvirus ofturkeys (HVT)
Human cytomegalovirus (HCMV)
Human herpesvirus 8 or Kaposi'sarcoma-
associated herpesvirus (HHV-8 or KSHV)
HIV-1
Hirame rhadovirus (HRV)
Marek's disease virus (MDV)
Murine grammaherpesvirus-68 (MHV-68)
Plum pox virus (PPV)
Red seabream iridovirus (RSIV)
Rotavirus
SARS coronavirus
Varicella-Zoster virus (VZV)
Viral hemorrhagic septicemia virus (VHSV)
White spot syndrome virus (WSSV)
Zaire Ebolavirus (ZEBOV), Reston Ebolavirus
(REBOV) and Marburgvirus (MARV)
(Yamagishi et al., 2003)
(Taylor et al., 2000)
(Pietiainen et al., 2000)
(Otsuka et al., 2003)
(Bigger et al., 2001)
(Mossman et al., 2001; Stingley et al.,
2000)
(Karaca et al., 2004)
(Chambers et al., 1999)
(Jenner et al., 2001; Nakamura et al.,
2003; Paulose-Murphy et al., 2001)
(de la Fuente et al., 2002; Geiss et al.,
2000; van 't Wout et al., 2003)
(Kurobe et al., 2005)
(Morgan et al., 2001)
(Ahn et al., 2002; Ebrahimi et al.,
2003; Martinez-Guzman et al., 2003)
(Pasquini et al., 2007)
(Lua et al., 2005)
(Cuadras et al., 2002)
(Leong et al., 2005)
(Cohrs et al., 2003; Jones and Arvin,
2003)
(Byon et al,, 2005)
(Khadijah et al., 2003; Liu et al., 2005;
Marks et al., 2005; Tsai et al,, 2004)
(Kash et al., 2006)
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these groups. Similarly, the temporal kinetic transcriptional profiles of RSIV in cell
culture in the presence or absence of de novo protein synthesis and viral DNA replication
inhibitors have already been described (Lua et al., 2005). In other studies, viral DNA
microarrays were used to compare the expression of viral genes during latency and 1ytic
replication (Cohrs et al., 2003; Ebrahimi et al., 2003; Jenner et al., 2001; Martinez-
Guzman et al., 2003). These studies provide a better understanding of viral gene
regulation strategies, pathogenic mechanisms as well as understanding of virus-host cell
interactions. In addition, DNA microarrays have also been applied to investigate the
correlation in expression patterns between unknown and known genes under the same
conditions. Because virulence-associated genes are often tightly and coordinately
regulated, candidate virulence factors are specifically expressed during infection and
likely to be co-regulated with known ones. Thus, such studies allow for the determination
of virulence-associated genes and for predicting their functions. Moreover, gene
expression studies based on the DNA microarray technology may also reveal key
regulatory differences that lead to differing virulence between closely related pathogen
strains or that account for differences in viral replication between different targeted-
cellslorgans of viruses (Cummings and Relman, 2000). A comparison of expression
profiles of known ORFs in AcMNPV by using a viral DNA microarray (Ac-BmNPV
chip) pointed up that most of genes involved in the viral life cycle were regylated
differently in two different cell lines, implying the different expression of these viral
genes accounts for the differences in viral replication between various targeted-cells
(Yamagishi et al., 2003).
   On the other hand, the DNA microarray technology is also involved in exploring host
cell transcriptional changes in response to virus infections (Bigger et al., 2001; Geiss et
al., 2000; Jones and Arvin, 2003). These studies promise to accelerate our understanding
of the host side of the host-pathogen interaction, contributing to armotation of
pathogenesis as well as host response to viral infections. The first application of DNA
microarrays to pathogenesis was to monitor global gene expression in primary human
fibroblasts infected by HCMV (Zhu et al., 1998). Among 6,600 spotted human genes,
258 transcripts changed by more than fourfold compared to uninfected cells at either 8 or
24 hours after infection. Some of these changes, such as induction of cytokines, stress-
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inducible proteins, and many interferon-inducible genes were consistent with induction of
cellular immune responses. By identifying factors expressed in the host under vaccination
or stimulation, the DNA microarrays promise to identify vaccine targets, provide a better
understanding of host defensive and virus-counter-defensive mechanisms, and contribute
guidelines for antiviral therapies (Byon et al., 2005; Kurobe et al., 2005; Yasuike et al.,
2007). In addition, a comparison of host responses to related strains of the same virus or
family can explain differences in pathogenesis. Comparison of gene expression responses
in human liver cells infected with Zaire Ebolavirus (ZEBOV), Reston Ebolavirus
(REBOV) and Marburgvirus (MARV) revealed different mechanisms involved in
antagonizing interferon (IFN) signaling pathways by the different members ofthe family
Filoviridae (Kash et al., 2006).
   Recently, to address the limitations of existing viral detection methodologies, DNA
microarrays derived from highly conserved sequence regions within viral families have
been utilized as diagnostic tools (Clewley, 2004; DeFilippis et al., 2003). Using available
sequence data from more than 140 sequenced viral genomes, DeRisi and colleagues
designed a long oligonuleotide (70-mer) DNA microarray with the potential to
simultaneously detect hurrdreds of viruses, including essentially all respiratory tract
viruses (Wang et al., 2002). Plant viral DNA microarrays were similarly constructed to
detect plum pox virus (PPV) and its strains (Pasquini et al., 2007). Historically, standard
viral detection techniques relied on isolation and in vitro viral culture or immunoassays
or even PCR methods can be used to determine the presence or absence of the virus
(Storch, 2000). However, in more complex biological situations, such as diseases where
many different viruses are present or where no etiologic agent has been identified, the
limitations ofthese methodologies become readily apparent. Some viruses are completely
refractory to in vitro culture, and immunoassays depend on the quality and availability of
the antiserum while PCR methods depend on the specificity of primers (Wang et al.,
2002). Thus, the potential use of this technology in routine diagnostics is versatile and
greatly expands the spectrum ofdetectable viruses in a single assay while simultaneously
providing the capability to discriminate among viral subtypes. Such a diagnostic tool will
undoubtedly have many uses in the study of viral pathogenesis and perhaps equally
important has the potential to facilitate novel viral discovery and identification of
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diseases ofunlmown etiology as well as in instances ofbioterrorism. Currently, the DNA
microarray teclmology has even known as highly parallel microbial diagnostic
microarrays (MDMs) because they have allowed rapid and simultaneous identification of
many different microorganisms, not only viruses in a single assay. Recent applications in
the MDM field were comprehensively recorded in a review by Loy and Bodrossy (Loy
and Bodrossy, 2006).
1.6 RNAInterference(RNAi)technology
L6.1 Baekground
   RNA interference (RNAi) was initially characterized in the nematode worm
CaenoThabditis elegans by Fire and colleagues, who found that double-stranded RNAs
(dsRNAs) induced a more potent sequence-specific silencing response than single-
stranded antisense RNA alone, which was customarily used for this purpose (Fire et al.,
1998). It soon turned out that RNAi is not restricted in nematode and can be induced in
fruitfly Drosophila melanogaster (Kennerdell and Carthew, 1998), parasites
Trypanosoma (Ngo et al., 1998), fimgi NeurospoTa crassa (Romano and Macino, 1992),
flowering plant Arabidopsis thaliana (Napoli et al., 1990; van der Krol et al., 1990), and
animals (Elbashir et al., 2001). These phenomena were termed "post-transcriptional gene
silencing" (PTGS) and "co-suppression" in plants, "quelling" in fungi, and "seqUence-
specific gene silencing" in animals. They are phenotypically different but mechanistically
similar forms of RNAi (Agrawal et al., 2003). The core of all these phenomena is the
processing oflong, double-stranded (ds)RNAs by the RNAse III enzyme Dicer into small
21-25 bp dsRNAs molecules, designated small interfering RNAs (siRNAs) and
microRNAs (miRNAs) (Dykxhoorn et al., 2003; Elbashir et al,, 2001; Hutvagner and
Zamore, 2002J Li and Ding, 2005). These small dsRNAs provide sequence specificity to
the related RNA-induced silencing complexes (RISCs), termed siRISC and miRISC,
respectively, and serve as guides for cleavage or inhibition of translation of mRNAs that
share sequence similarity with the dsRNA trigger.
   In the nematode C elegans, the first metazoan in which RNAi was documented,
silencing can be experimentally induced by injection, feeding or transgenic expression of
dsRNA molecules (Fire et al., 1998; Grishok, 2005; Grishok et al., 2005). The systemic
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nature of RNAi in C. elegans is a striking example of the ability of cells to detect and
internalize extracellular dsRNA to initiate intracellular gene silencing events. A number
of cells can naturally take-up exogenous dsRNA and use it to initiate RNAi silencing
(Clemens et al., 2000; Worby et al,, 2001). Thus, RNAi has been widely employed to
manipulate gene expression, elucidate signal pathways and identify gene functions
(Agrawal et al., 2003; Haasnoot et al., 2003). Insurmountable evidences also pointed out
the efficiency of RNAi in mounting antiviral responses.
1.6.2 Small interfering RNA (siRNAs) and microRNA (miRNAs) molecutes:
      deL17nition, origin andfunctionality
   Small molecules of dsRNAs, mediators of RNA-related gene silencing mechanisms,
are classified into siRNAs and miRNAs based on their origin and function (Tang, 2005;
Zheng et al., 2005).
   siRNAs are small RNAs that are produced in the cytoplasm by Dicer-mediated
cleavage of long double-stranded RNA that has been formed by base pairing between two
independent transcripts (Sarnow et al., 2006). The long dsRNAs are normally produced
from foreign genomes, such as virus infections or transposons. In the cytoplasm of cells,
siRNAs are incorporated into RISC containing siRNA (siRISC) for cleavage ofthe.target
mRNA with perfect complementary in sequence (Sledz and Williams, 2005) (Fig. 3).
   In contrast to siRINAs, miRNAs are small RNAs that are produced by Drosha- and
Dicer-mediated cleavage of RNA-hairpin structures that are encoded in cellular and viral
genomes (Sarnow et al., 2006). miRNAs are most often transcribed by RNA polymerase
II and the resulting primary miRNAs (pri-miRNAs) are processed in the nucleus by the
RNAse type III Drosha to produce precursor miRNAs (pre-miRNAs). Pre-miRNAs are
then exported to the cytoplasm by Exportin-5 and processed into mature miRNAs
through the action of Dicer. miRNAs are incorporated into RISC containing miRNA
(miRISC) and guide for their mRNA targets. Unlike siRNAs, miRNA-armed RISC can
enforce either degradation ofmRNA (in the case ofperfect sequence complementarity) or
inhibition of mRNA translation (in the case of imperfect sequence complementarity)
(Sullivan and Ganem, 2005; Triboulet et al., 2007) (Fig. 3).
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  After the milestone discovery ofthe first miRNA in 1993 (Misk4 2005), hundreds of
miRNAs are discovered in nematodes, fi'uit flies and humans, and it comes as no surprise
that viruses, which typically employ many components of the host gene expression
machinery, also encode miRNAs (Kim and Nam, 2006). To date, 73 viral miRNAs have
been identified in genomes of 7 viral species, including EBV, KSHV, HCMV, MHV68,
HSVI, SV40 and rhesus lymphocryptovirus (rLCV) (Pan et al., 2007). It is believed that
many miRNAs are ubiquitously expressed, whereas others are expressed in a cell-type-
specific manner. A single miRNA can target transcripts from multiple genes and,
conversely, several miRNAs can control a single target. Therefore, miRNAs and their
targets function as a complex regulatory network (Nair and Zavolan, 2006). miRNAs
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influence diverse cellular processes ranging from embryonic development, cellular
differentiation, proliferation, apoptosis and metabolism to cancer. A recent study showed
that cellular miRNAs have direct antiviral effects in addition to their regulatory functions
(Lecellier et al., 2005). In particular, as reviewed by Nair and Zavolan (Nair and
Zavolan, 2006), virus-encoded miRNAs are involved both in the regulation oftheir own
genes and in the subversion ofcellular defense mechanisms.
1.6.3 Application ofRNAi technology in virological studies and R7VA-based antiviral
      approaches
   Significant advances in the RNAi technology, together with the completion of several
viral genome sequences, paved the way for new approaches in studying molecular
virology. It has been applied to study disease-related genes and elucidate their roles in the
viral cycle and in virus-host cell interactions as well as to investigate cellular pathways
involved in viral pathogenesis (Colbere-Garapin et al., 2005).
   RNAi-based option is considered to be of tremendous potential as an antiviral
approach against a wide variety of viruses in plants, invertebrate and vertebrate systems.
In plants, RNA silencing in the context of viral infections has been extensively studied
and is well established that it functions as adaptive antiviral immune response, although
viruses have evolved strategies to suppress the RNA-silencing pathways as a counter-
defense (van Rij and Andino, 2006). In insects, RNAi pathway was reported to direct
innate immunity against viruses. An evidence showed that fiock house virus (FHV), a
member of the Nodaviridae family, is targeted by the RNAi machinery in the insect
Drossophila (Wang et al., 2006). Furthermore, several studies have established that
RNAi-based antiviral approach protects insects from viral infection (Keene et al., 2004;
Sanchez-Vargas et al., 2004). Introduction of dengue virus genomic sequences with a
Sindbis virus vector into cells of the mosquito Aedes albopictus resulted in RNAi-based
resistance to subsequent challenges with dengue virus (Sanchez-Vargas et al., 2004).
Current reports revealed the existence ofboth innate (non sequence-specific) and RNAi-
related (sequence-specific) antiviral phenomena ip other invertebrates, such as
crustacean, as reviewed by Robalino et al. (Robalino et al., 2007).
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   In vertebrate system, it has long been thought that dsRNA, a common virus-
associated molecular pattern, is a potent inducer of non-specific immune mechanism
involving interferon response, implying RNAi ineffectivity for gene sequence-specific
silencing in interferon-producing organisms like mammals (Dykxhoorn et al., 2003;
Robalino et al., 2005; Schott et al., 2005). However, the pioneering work by Elbashir et
al. (Elbashir et al., 2001) showed that 21-22 nucleotide siRNAs are able to silence genes
in a sequence-specific manner, considered as a breakthrough in RNAi studies. This was
followed by an outburst of reports that dsRNAs of less than 30 nucleotides bypass the
IFN-induced pathways and evoke RNAi-type silencing (Caplen et al., 2001; Dave and
Pomerantz, 2003). Thus, RNAi-like mechanisms are also believed to act as an antiviral
defense in vertebrates (Browne et al., 2005; Karpala et al., 2005; Li and Ding, 2005) and
can be induced through the introduction ofnaked siRNAs and plasmid expressing short-
hairpin (sh)RNAs or pre-miRNAs into cells from the outside (Elbashir et al., 2001;
McManus et al., 2002). Plasmid-based expression systems using RNA polymerase II
(Pol II) or III (Pol III) promoters have been commonly used (Dykxhoorn et al., 2003). A
model of expression vector using Pol II promoter, Block-iT Pol II miR RNAi expression
vector with EmGFP, is shown in Fig. 4. This vector is designed to allow cloning ds oligo
duplexes encoding a pre-miRNA target sequence and permit high-level expression ef the
pre-miRNA through co-cistronic expression of EmGFP in most mammalian cells. The
expression vector includes flaking and loop sequences from an endogenous murine miR-
155 which allow proper processing of the engineered pre-miRNA sequence. Additionally,
the vector also contains resistance genes for selection of positive clones in E. coli and
stable cell lines that stably expressing the miRNA (Invitrogen, Catalog no. K4936-OO).
     Introduction of naked viral-gene specific siRNAs or plasmid expressing virus-
derived miRNAs into cells may lead to inhibit viral gene expression and block viral
replication (Zheng et al., 2005). When naked viral-gene specific siRNAs are delivered to
cells, they directly guide siRISC.without processing by Dicer to their homologous target
mRNAs for cleavage. On the other hand, the use of plasmid expressing virus-derived
shlUNIAs or pre-miRNAs is the dependency on Dicer processing. Virus-derived shRNAs
or pre-miRNAs are expressed by nucleus enzymes arid processed by Dicer into mature
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miRNAs prior to being guided to miRISC
mRNAs (Dykxhoorn et al., 2003).
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   Roles ofviral gene-specific siRNAs and virus-derived pre-miRNAs as antiviral tools
are proposed in Fig. 5 and Fig. 6, respectively. Thus, RNAi has been currently considered
as a gene-specific therapeutic option for controlling viral infections in many ways, such
as, inhibiting the expression of viral antigens and accessory genes, controlling the
transcription of viral genome, hindering the assembly of viral panicles or blocking viral
replication (Tan and Yin, 2004). RNAi mediated by artificial introduction of viral-
specific siRNAs or shRNAs has been successfu11y used to inhibit viral replication of
mammalian viruses both in a cell culture system and an experimental animal model,
although the outcome of individual RNAi events varies depending on the designed RNAi
and their target regions, as well as the escape from RNAi-mediated suppression ofviruses
through mutations within the targeted regions (Zheng et al., 2005). Poliovirus was one of
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the first to be tested for siRNA-mediated sequence-specific inhibition. HeLa cells
transfected with an siRNA specific for a capsid protein or viral polymerase before
infection with Poliovirus markedly reduced the titer of virus progeny (Gitlin et al.,
2002). Studies on HIV-1 inhibition by RNAi showed that almost a complete inhibition of
HIV-1 production was obtained by the combined expression of siRNAs against Tat and
Rev genes (Lee et al., 2002), and HIV-1 production in T-lymphocytes expressing
shRNAs targeting Nef gene was reduced to more than 1O-fold, and virus replication was
inhibited upto 1,OOO-fold 20 days post-infection (Haasnoot et al., 2003). siRNA
molecules targeted to different genome segments of influenza virus, a virus responsible
for acute upper respiratory disease causing an estimated 500,OOO deaths each year, were
also tested and shown that siRNA effectively inhibited virus replication not only in vitro,
but also in mice in vivo (Stram and Kuzntzova, 2006). Various mammalian viruses were
targeted for RNAi-based antiviral studies both in vitro and in animal models (Table 4 and
5). Almost all these studies have used synthesized viral gene-specific siRNAs or plasmids
expressing viral-derived shRNAs, which were introduced into cells either shortly before
or after challenge with viruses.
   In aquatic animal viruses, applications of RNAi-based antiviral approaches have been
ill-studied but this strategy has been reported to be effective against two marine
crustacean viruses, including wnite Spot Syndrome Virus (WSSV) and Yellow Head
Virus (YHV), and two marine fish viruses, including Tiger Frog Iridovirus (TFV) and
Viral Hemorrhagic Septicemia Virus (VHSV) (Table 6). Using dsRNA specific for
WSSV, a model of antiviral immunity in shrimp was proposed, by which viral dsRNA
engages not only innate immune pathways but also an RNAi-like mechanism to induce
potent antiviral responses in vivo (Robalino et al., 2005). Similarly, YHV•-specific
dsRNAs were effectively inhibited YHV replication in both shrimp primary cell culture
and in the shrimp Penaeus monodon (Tirasophon et al., 2005; Yodmuang et al., 2006).
Unlike aquatic invertebrates such as shrimp, virus-specific siRNAs, instead of using
virus-specific long dsRNAs, were used in RNAi-based antiviral approaches in aquatic
vertebrates such as frog and fish.
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Table 4 : RNAi-mediated suppression ofmammalian virus replication in cell culture
                         system
Mammalian RNA virus RNAi References
Avianmetapneumovirus(AMPV) siRNA (Ferreira et al., 2007)
Coxsackievirus B3
Enterovirus 71 (EV71)
Foot-and-mouth disease virus
Hepatitis A virus
Hepatitis C virus
Hepatitis delta virus
HIV-1
Human parainfluenza virus-3
Human rhinovirus 16
Influenza A virus
Poliovirus
Respiratory syncytial virus
Rotavirus
SARS-associated CoV
Vaccinia virus
Venezuelan equine encephalitis
virus (VEEV)
Vesicular stomatitis virus
West Nile virus
siRNAIshRNA
siRNA
shRNA
siRNA
siRNA/shRNA
siRNA
    '
siRNAIshRNA
siRNA
siRNA
siRNAIshRNA
siRNA
siRNA
siRNA
siRNA
siRNA
siRNA
siRNA
shRNA
(Kim et al., 2007; Yuan et al.,
2005)
(Sim et al., 2005)
(Chen et al., 2004)
(Kanda et al., 2004; Kanda et
al., 2005)
(Kronke et al., 2004; Yokota
et al., 2003)
(Chang and Taylor, 2003)
(Capodici et al., 2002;
Huelsmann et al 2006'
                         '         -p
Novina et al., 2002)
(Barik, 2004)
(Phipps et al., 2004)
(Ge et al., 2003; McCown et
al., 2003)
(Gitlin et al., 2002)
(Bitko and Barik, 2001)
(Dector et al., 2002)
(He et al., 2006; Wang et al.,
2004; Wu et al., 2005; Zhao
et al., 2005)
(Dave et al., 2006)
(O'Brien, 2007)
(Barik, 2004)
(McCown et al., 2003)
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Table 5: Use of RNAi in in "ViVO animal models ofvirus infections
Virus RNAi Method of delivery References
SAR-associated CoV
West Nile Vims
Foot and mouth
disease virus
Respiratory syncytial
virus
Parainfluenza virus
Influenza A virus
Hepatitis B virus
siRNA
siRNA
shRNA
siRNAIshRNA
siRNA
siRNAIshiUslA
siRNA
siRNAIshRNA
siRNA!shRNA
Intramuscular injection
Hydrodynamic injection
Subcutaneous injection
Intranasal delivery
Intranasal delivery
Intravenous injection
Hydrodynamic injection,
intranasal delivery
Hydrodynamic injection
Intravenous injection
(Zhao et al., 2005)
(Bai et al., 2005)
(Chen et al., 2004)
(Bitko et al., 2005;
Zhang et al., 2005)
(Bitko et al., 2005)
(Ge et al., 2004)
(Tompkins et aL,
2004)
(Giladi et al., 2003;
McCaffrey et al.,
2003)
(Morrissey et al.
2005; Uprichard et al.,
2005)
Table 6 : RNAi-mediated suppression of aquatic animal virus re plication
Virus RINAi Method of delivery References
Tiger frog iridovirus
(TFV)
Viral hemorrhagic
septicemia virus (VHSV)
Yellow head virus (YHV)
White spot syndrome
virus (wssv)
siRNA
siRNA
dsRNA
dsRNA
Transfection (cell culture)
Transfection (cell culture)
Transfection (primary cell
culture) or inj ection
(shrimp)
Inj ection (shrimp)
(Xie et al., 2005)
(Schyth et al.,
2006)
(Tirasophon et al.,
2005; Yodmuang
et al., 2006)
(Robalino et al.,
2005)
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   The inhibition of TFV replication by siRNAs targeting the MCP gene was
demonstrated by reduced MCP RNA Ievel, postponed emergence of cytopathogenic
effect, as well as reduced virus titer and particles in fish cells (Xie et al., 2005).
Consistent with the activation of RNA by siRNAs, siRNAs specific to the viral
glycoprotein gene ofVHSV efficiently inhibited viral replication in infected cell cultures,
while the corresponding mismatched siRNAs did not exhibited this antiviral effect
(Schyth et al., 2006). Such studies significantly establish RNAi as a potential approach to
therapy ofviral diseases in aquaculture.
1.7 Obj ectives and contents of the study
   Disease problems particularly of viral origin have continuously plagued the
aquaculture industry due to rapid intensification of farming practices. Moreover, the
control of viral infection is difficult and complex because of the Iimited effectiveness of
existing antiviral agents and the high speed mutation rate of the viral genome (Lee and
Rossi, 2004). Toward this end, understanding the pathogenic mechanisms of viral
infections at the molecular level and the development of alternative antiviral approaches
based on advances in molecular genetic technology will be of enormous contribution to
the control ofviral diseases.
   This study aimed to better understand of the molecular pathogenic mechanisms of
viral infections in fish using RSIV, a marine-pathogenic iridovirus, as a model based on
DNA microarray technology, and to develop alternative approaches against iridoviral
infections using RSIV-specific siRNAs and miRNAs as antiviral tools based on RNAi
teclmology, instead ofvaccination technology. Specific objectives ofthe study are:
1. to explore the transcriptional profile of RSIV over the time-course of virus
     infection in a fish model
2. to investigate differential gene expression patterns between RSIV-infected spleen
     and kidney in order to find out a suitable organ for diagnosis of iridoviral diseases
     at the molecular level
3. to generate and test the potential antiviral activity ofviral gene-specific siRNAs on
     RSIV replication in a cell culture system
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4. to generate and test the potential antiviral activity of virus-encoded miRNAs on
     RSIV replication in a cell culture system
   The contents ofthis research study are:
1. Chapter 1 (General introduction) provides the backgroufid on global views of the
     research study.
2. Chapter 2 (The pathogenesis of RSIV infection as revealed by viral DNA
     microarrays) provides understanding of the molecular pathogenic mechanism of
     RSIV infection in fish and further confirms, at the molecular level, that the spleen
     is a suitable organ for diagnosis of iridoviral diseases, resulting in the thorough
     knowledge ofiridovirus infection in fish.
3. Chapter 3 (Inhibition of RSIV replication by viral gene-specific siRNAs in a cell
     culture system) evaluates anti-RSIV activity of viral gene-specific siRNAs on
     RSIV replication in vitro, providing a promising alternative antiviral approach
     based on siRNA-related pathways.
4. Chapter 4 (Engineered virus-encoded pre-microRNA (pre-miRNA) induces
     sequence-specific antiviral response in addition to non-specific immunity in a fish
     cell line: Convergence of RNAi-related pathways and IFN-related pathways in
     antiviral response) investigates antiviral activity of viral-encoded microRNAs
     (miRNAs) on viral replication in vitro, providing another option for combating
     iridoviral infections utilizing the antiviral potency of miRNA-related pathways, as
     well as better understanding the complex miRNA-related mechanisms.
5. Chapter 5 (General conclusion and perspectives) provides a comprehensive
     discussion of the proceeding studies, and further discuss perspectives for the use of
     the antiviral potency ofRNAi to control ofviral diseases in aquaculture.
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CHAPTER 2
THE PATHOGENESIS OF RED SEABREAM tR/DOVtRUS (RStV)
 INFECTION AS REVEALED BY VIRAL DNA MICROARRAYS
45
Abstract
   Red seabream iridovirus (RSIV) disease is a serious disease of many marine fish
species in Japan and elsewhere. To better understand the molecular pathogenic
mechanism, we examined the transcriptional profile of RSIV in infected fish using a
DNA microarray. Expression ofRSIV open reading frames (ORFs) was first detected at
about 5 days post-infection (d.p.i.), and accounted for about 450/o oftotal ORFs. Almost
all the ORFs (970/o-990/o) were expressed at their maximum levels during 7-9 d.p.i. The
expression levels and the number of expressed ORFs started to decrease at 1O d.p.i. These
results suggest that pathogenesis ofRSIV infection began at around day 5, and continued
with high levels of viral multiplication until viral clearance by host antiviral defenses
starting from around 10 d.p.i. A comparison of viral gene expression pattems in the
spleen and kidney over the course of the infection clearly provides a better understanding
of the viral pathogenesis in different host cell types, and further suggests that RSIV
preferentially targets the spleen. The spleen may thus be a susceptible organ for diagnosis
of iridoviral disease.
Keyvvords: DNA microarrays, RT-PCR, iridoviruses, RSIV, pathogenesis.
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2.1 Introduction
   Systemic iridoviral infections have caused high mortality in cultured freshwater and
marine fish species in many parts ofthe world (Chao et al., 2004; Iwamoto et al., 2002;
Qin et al., 2003). Outbreaks ofthese diseases have been reported in Australia, France,
Germany, Finland, Denmark, United State, Taiwan, Southeast Asia and Japan (Huang et
al., 2004). In Japan, an iridoviral disease has been recorded in at least 31 marine fish
species (Kawakami and Nakajima, 2002), The iridoviral pathogen was first isolated from
red seabream (Pagrus maJ'or) in 1992 and named red seabream iridovirus (RSIV), and
thus the disease was called as red seabream iridoviral disease (RSIVD) (Inouye et al.,
1992). RSIV-infected fish showed disease symptoms from 5 days of infection, and
mortality commenced at day 6 and increased up to 900/o at day 9 (Oshima et al., 1998).
The infected fishes displayed enlarged cells in spleen, kidney, liver and gills (Inouye et
al., 1992). A similar disease has recently been documented in some other Asian countries
(Chao et al., 2002; Chou et al., 1998; Do et al., 2004; Jeong et al., 2003; Mahardika et
al., 2004; Wang et al., 2003). Due to the devastating effects of this pathogen to marine
aquaculture, various rapid and sensitive diagnostic methods, as well as some control
strategies have been developed for RSIV (Caipang et al., 2004; Caipang et al., 2003;
Caipang et al., 2006; Jeong et al., 2004; Kurita et al., 1998; Nakajima, 1995; Oshima et
al., 1998; Oshima et al., 1996). However, liule is known about the pathogenic
mechanism and the most susceptible organ to iridoviral infection in molecular detail.
Gene expression is a molecular indicator for the annotation of mechanisms underlying
normal cellular processes as well as the molecular basis for disease (Clewley, 2004).
Therefore, studies of RSIV gene expression patterns are necessary and usefu1 for
understanding of the viral molecular pathogenic mechanism, and hence importance of
DNA microarray technology, a powerfu1 tool of examining gene expression.
   The uses of DNA microarray technology in molecular virology have been reviewed
(Clewley, 2004; Cummings and Relman, 2000; Hanington et al., 2000; Ye et al., 2001).
Its potential benefits are able to accelerate the annotation ofvarious aspects ofboth sides
of complex virus-host interactions in molecular detail. Viral gene-derived DNA
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microarrays provide a better understanding of the viral DNA replication and gene
expression strategies; identify virulence-associated genes and their roles involved in viral
pathogenesis; and provide possible clues for the pathogenesis of the virus. Moreover, the
DNA microarrays derived from highly conserved sequence regions within viral families
have been currently utilized as promising diagnostic tools (Pasquini et al., 2007; Wang
et al., 2002). On the other hand, host gene-derived DNA microarrays provide a better
understanding of host response at the level of gene expression and provide a molecular
description of the events that follow the viral infection, as well as explain differences in
pathogenesis between related strains ofthe same virus or family (Cummings and Relman,
2000; Kash et al., 2006).
   This technology is well suited for genome-wide transcription studies, and is
especially usefu1 for detemiining the complex transcriptional program of large DNA
viruses (Chambers et al., 1999; DeFilippis et al., 2003). It has been successfu11y used to
explore viral gene expression patterns of mammalian and aquatic viruses at different
replication stages of viral life cycle or under different conditions both in cell culture
systems (Ahn et al., 2002; Chambers et al., 1999; Ebrahimi et al., 2003; Lua et al.,
2005; Paulose-Murphy et al., 2001) and experimental animal models (Liu et al., 2005;
Marks et al., 2005; Martinez-Guzman et al., 2003; Rochford et al., 2001; Tsai et al.,
2004). It has also been used to explore the variability in transcriptional activity for every
gene between closely related pathogen strains or between different targeted cellslorgans
of viruses (Cummings and Relman, 2000). By usting a DNA microarray of baculovirus
genomes (Ac-BmNPV chip), differential gene expression of autographa californica
multiple nucleopolyhedrovirus (AcMNPV) involving in the viral life cycle were revealed
between two susceptible insect cell lines, implying the different expression of these virai
genes accounts for the differences in viral replication between different targeted-cells
(Yamagishi et al., 2003).
   We used RSIV as a model to explore the iridoviral transcriptional profiles during the
course of an infection both in cell culture and fish model studies by using viral DNA
microarrays. Our previous studies in a cell culture system (Lua et al., 2005) provided a
better understanding of the RSIV DNA replication and gene regulation strategies.
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However, another interest was to focus on the molecular pathogenic mechanisms of the
virus. To this end, we examined transcriptional profiles of RSIV in infected spleen and
investigated differences in viral gene expression between spleen and kidney over the
time-course of an in vivo infection in a fish model. We have shown here, for the first time,
in vivo genome-wide transcription program of an iridovirus by using DNA microarray
                                                        'technology. The present study provided a greater understanding of the molecular
pathogenic mechanisms and explored, at the molecular level, a susceptible organ, for
RSIV infection, and hence possible clues for early viral screening. Such studies will be of
enormous contribution to the thorough of knowledge of RSIV infection and control of
iridoviral diseases.
22 Materialsandmethods
2. 2. 1 Cetl culture and virus stock
   Grunt fin (GF) cells (Clem et al., 1961) were maintained at 250C in minimum
essential medium (MEM) (Invitrogen, USA) supplemented with 1OO/o fetal bovine serum
(JRH Biosciences, Lenexa, KS, USA), 100 IU/ml of penicillin, and 100 ptglml
streptomycin for virus propagation. RSIV stock was prepared in GF cells as previously
described (Lua et al., 2005). The virus titer was determined using the 500/o tissue culture
infective dose (TCIDso) standard method (Reed and Muench, 1938).
2.2.2 In vivo virus infection andtime-coursesampling
   Red seabream juveniles were experimentally injected with 150 pl of the RSIV
inoculum (5.0 X 105 TCIDselml) and held in tanks supplied with running seawater at
250C. Control fish were injected with the same volume of phosphate buffered saline.
Thirty fish were sacrificed immediately after the RSIV infection and were referred to as O
day post-infection (d.p.i.) fish. Alive fish showed lethargic, severe anemia, petechiae of
gills was selected for sampling. Five fish were randomly sampled from the experimental
population on each of 2, 3, 5, 7, 9, 10, and 14 d.p.i. The spleens and kidneys were
removed from these fish and stored in RNAIater (Ambion, USA) according to the
manufacturer's protocol.
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2.2.3 Monitoring ofRSIVtranscri tionalprofiles during in vivo infection
   To examine changing RSIV gene expression levels in infected organs, total RNA was
isolated from RSIV-infected spleens at times up to 14 d.p.i. and reverse transcribed to
cDNA. cDNA target samples derived from time-course RNA samples were hybridized
against cDNA control samples derived from O d.p.i. RNA samples on viral DNA
microarray chips.
2.2.4 Monitoring of dbjferentially RSIV transcriptional profites in viral-infected
      spleen and kidney
   To investigate whether RSIV genes were differentially expressed in different
targeted-organs and to further explore a susceptible organ for RSIV infection, total RNA
was extracted from both RSIV-infected spleens and kidneys at times up to 14 d.p.i. and
reverse transcribed to cDNA. At each indicated time point, cDNA target samples derived
from the spleens were hybridized against cDNA control samples derived from the
kidneys on viral DNA microarray chips.
2. 2. 5 RNA preparation and labeled cDNA target construction
   Total RNA was extracted from the collected spleens and kidneys with TRIzol
(Invitrogen, USA) and subjected to DNase I treatment (Promega, USA) according to the
manufacturers' protocols. For each time-course target sample and control sample, cDNAs
were generated from 50 ptg total RNA using an RSIV antisense-strand specific primer
mixture. The cDNAs were first labeled with aminoallyl-dUTP using a LabelStarTMArray
Kit (Qiagen, USA) and purified with a QIAquick PCR Purification Kit (Qiagen, USA)
following the manufacturer's recommendations. The target and control aminoallyl-
cDNAs were then coupled with Cy5- and Cy3- monofunctional dyes (Amersham
Biosciences, UK), respectively, and purified with MinEluteTM Spin columns (Qiagen,
USA) according to the manufacturer's instructions.
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2.2.6 ConstructionofRSIVDNAmicroarraychi andmieroarrayhybridization
   The DNA microarray chips containing almost putative RSIV ORFs (92 ORFs) and
control genes used in this study were prepared exactly as described by Lua et al. (2005).
Briefly, RSIV ORFs fragments (approximately 300 to 1500 bp in length) were amplified
by PCR using viral genome as a template and specific primer sets. All PCR products
showing a single band of the appropriate size by gel electrophoresis were purified, and
reconstituted in TE buffer at a final concentration of about 500 pglml for construction of
microarray chip. Piscine P-actin genes from Japanese flounder and red seabream were
included as internal controls to normalize the microarray data. In addition, distilled water
was also used as a negative control. Each targeted probe was spotted in duplicate at
different parts of the chips to assess the consistency of hybridization and facilitate
comparison during the analysis. At each indicated time point, the Cy51Cy3-dUTP labeled
cDNAs were combined and hybridized to the microarray chips for 16-18h at 42oC. The
chips were rinsed several times and finally dried following the DNA microarray method
(Bowtell and Sambrook, 2002.) as modified by Lua et al. (Lua et al., 2005).
2.2.7 Statisticaldataanalysis
   The microarray chips were scanned using a GenePix 4000B array scanner and images
were analyzed by GenePix Pro 4.0 array analysis software (Axon Instruments, Inc., USA).
The Cy5 and Cy3 signal intensities were normalized to equilibrate them with the signal
intensity ofa spotted housekeeping gene (the P-actin gene) that was set to 1.
   The median signal intensity, which was subtracted from the background signal, was
used as an appropriate measure of absolute viral gene expression in infected spleens.
Only genes exhibiting signal intensities at least two-fold greater than the signal intensities
ofthe reference samples collected at O d.p.i. were used for statistical analysis.
   The ratio of medians and the cut-off method were used as appropriate differential
measure of viral gene expression between spleen and kidney. Genes with median ratios
from 2.0 were considered as up-regulated; genes with median ratios less than O.5 were
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considered as down-regulated, and genes with median ratios ranging between O.5 and 2.0
were considered as unchanged (Byon et al., 2005; Kurobe et al., 2005).
   The significance of differences between target samples and reference (control)
samples was determined with a paired t-test on replicated spots for each gene. p values of
less than O.05 were considered significant. The microarray data was also imported into
the cluster program 3.0 in conjunction with an average linkage hierarchical clustering
algorithm using Euclidian distance as the similarity metric. The cluster analysis allowed
grouping of RSIV ORITs with similar expression patterns, and presenting expression
levels of each ORF based on color-coded. After clustering, the results were visualized in
a tree structure by using a tree view program (Eisen et al., 1998) .
2.2.8 Reverse Transcri tion (RT)-PCR
   A two-step RT-PCR assay, in which cDNA is first synthesized and then used in PCR,
was used to determine expression of several RSIV ORFs for confirrning the microarray
data. Twenty pl of cDNA was synthesized from 5 pg total RNA derived from spleens and
kidneys by using M-MLV Reverse Transcriptase (Invitrogen, USA) according to the
manufacturer's protocols. RT-PCR was carried out in a 30 pl reaction volume containing
1 pl cDNA using Taq polymerase. The same specific primers for each RSIV ORF used in
the amplification of microarray probes were also employed here. The levels of B-actin
mRNA, which are assumed to be constant over most experimental conditions and used as
an internal control for microarray norrnalization, were also monitored by using a similar
procedure. Cycling parameters consisted of an initial denaturation at 950C for 2 min,
followed by 23 - 27 cycles of denaturation at 950C for 30 sec, annealing at 550C for 30
sec and elongation at 720C for 1 min, and a final elongation step at 720C for 5 min. PCR
cycles were optimized to determine differences in expression of RSIV transcripts
between spleen and kidney at different stages ofthe infection. A 23 cycle PCR was used
to deterrnine differences in expression at the high level spread stage of the infection (7-9
d.p.i.) while a 27 cycle PCR was performed to show differences in expression at the early
stage (5 d.p.i.) and late stage (1O-14 d.p,i.) of the infection.
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2.2.9 Determination ofinfectious viral eoncentration in spleen andkidney (TCJD50
      assay)
   RSIV was obtained from spleens and kidneys that were collected from RSIV-infected
red seabream during 7 - 9 d.p.i., and was propagated in GF cells as previously described
(Lua et al., 2005). TCIDso assay was used to determine the infectious viral concentration
ofRSIV stocks derived from spleens and kidneys. The cells were daily observed for CPE
indicative of viral replication and virus titer was calculated following the TCIDso
standard method (Reed and Muench, 1938).
2.3 Results
2. 3. 1 In vivo RSIV transcrip tion program
   The microarray analysis showed that no viral transcripts were detected in infected
spleens at 2 and 3 d.p.i. (data not shown), but viral transcripts showed significant changes
in expression from 5 d.p.i. onwards. At 5 d.p.i., 44 viral ORFs were significantly
expressed, accounting for about 44.60/o (p < O.05) of total RSIV ORFs. Almost all (about
970/o to about 99e/o, p < O.OOI) of viral ORFs were significantly expressed during the
period 7-9 d.p.i. (Table 1). As shown by the cluster analysis (Fig. 1), the expression
levels of viral ORFs were at their maximal levels during this period, showing high levels
of viral multiplication. However, the numbers and the expression levels of expressed
ORFs started to decrease at 10 d.p.i. The expression of only 250/o (p < O.05) of the ORFs
was detected at 14 d.p.i. (Table 1 & Fig, 1).
2.3.2 DifferentiatRSIVgene expressionproLfites in viral-infectedspteen andkidney
   A comparison of RSIV gene expression profiles between viral-infected spleen and
kidney at various time points following an in vivo infection, as determined by the RSIV
DNA microarray analysis, were detailed in Table 2 and summarized in Table 3, No viral
transcripts were detected in either spleens or kidneys at 2 and 3 d.p.i. (data not shown),
but viral transcripts were detected starting at 5 d.p.i. (Table 2 & Fig. 2). As shown in
detail in Table 2 or summarized in Table 3, all viral genes were expressed at higher levels
or no differences in expression in the spleens when compared with those in the kidneys
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throughout the infection. In particular, all viral genes were expressed at higher Ievels in
the spleens during the period 7-9 d.p.i. At day 7 after infection, about 600/o of expressed
genes showed more than tenfol-d difference in expression between spleens and kidneys
(Fig. 2).
2.3.3 Reverse transcri tion (RT) -I'CR analysis
   Seven RSIV ORFs were selected for confirming the microarray results by RT-PCR
(Fig. 3). Theses ORFs included IE transcript 097R that is associated with trans-activation
factors, E transcripts 092R, 324R, 407R and 618R that have been predicted to be
involved in viral DNA replication mechanisms, and L transcripts MCP (Major capsid
protein) and 291L that have been predicted to encode structural proteins ofthe virus. The
B-actin transcript was used as an internal control.
   As expected, no viral band was observed at day 2 or day 3 of the infection.
Differences in expression of these ORFs between spleens and kidneys during the
spreading stage of the virus (7-9 d.p.i.) were detected after both 23 and 27 PCR cycles
(Fig. 3A & 3B), while the differences at the early stage (5 d.p.i.) and late stage (10-14
d.p.i.) ofthe infection were detected after 27 PCR cycles (Fig. 3B). The expression levels
ofthe selected ORFs were all higher in the spleen than in the kidney. In addition, the 6-
actin transcript levels, as determined by RT-PCR, were similar between samples,
confirming that the B-actin gene can be used to normalize the viral gene expression
results across the microarrays.
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Table 1. Microarray analysis ofRSIV transcription program in vivo
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241
470191
439
O.45
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193117Oza2tt
1,311.a4O,33
e.114.422,70O.76
Hypotheticalprotein
Hypothetscalprotem
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Hypotheticalprotein
Hypotheticalpretein
Hypotheticalprotein
Hypotheticalpretein
Hypotheticalprotein
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7a5
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463385209'S6S2'l3
171573674i396'
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31112g,
S17167
363125
1441
O.86O.g5O.36
V.6VU.60
O.IB1.621,49a.69
O,092.221,g4O.39
O.52O,69O,22'
O.10O.731,14029
o.4so.goo,22
O.25O.32
LELEEEEEE
283'
92396
2SS
137
22419057821027110
27741411203362122'
13921431201•70g
141IS38
O.243.531.731.79O.22
O.Z97.672.e6O,e3O.2S
O.153.972.EE1.23
O.152.851.27a.26Putativeankvrinrepeatpratein 576149
ExpressedOR.Fs(Ofo) 44.6S98,9++96.7+k.79.3+t2Sk
a Signal intensity value is the background-subtracted median value
b The calibrated expression ratio is the ratio of the expression ofthe RSIV ORF in viral-infected cells compared to the B-actin control gene
C Abbreviation: IE, Immediate--Early; E, Early; L, Late; ND, Not Detected (adapted by Lua et al. 2005)
*(p < O.05); **(p < O.OO1)
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Fig. 1: Hierarchical cluster analysis of RSIV transcription program in vivo. calibrated
expression ratios for each ORF were categorized by an average linkage hierarchica1 clustering program.
Each rovv represents the expression profile of a single ORF, and each co1umn indicates time points after
infection. The normalized expression levels across al1 the time points are colorÅëoded. Green boxes indicate
expression ratios lower than the mean. Red boxes indicate expression ratios greater than the mean. Black
boxes indicate an intermediate level of expression and gray boxes indicate missing or not detected. The
magnitude of up-regulation tfom the mean is shown by differing intensities of red, with deep red showing
lower expression and bright red showing the highest levels of expression.
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Table 2. Comparison ofRSIV gene expression profiles between spleen and kidney
Accession Foldchange
INo ORF FutativeFunetion No. 5d.p.i.7 d.p.i.9d.p.i. IOd.p.i. 14d.p.L
1 P.li.iFO16L Hypothetiealproteip...........-. .?.i[ 2,2 e.,5.. u
•2 ORFO18RHypotheticalproteipw.m..... 15.2 3,e 1.5 1.8
I3 ORF029RHypotheticalprotein g,s 3.9 1.4
l4 ORFe33RCytesineDNAme.thyltransferase AAW1S61 12 7,g 3,4 1.7i•
ls ORF.P.3.7RHypotheticalprgteip... 3.1 3,E Sl 2.1. 1,9
6 ORIF042RHypotheticalpretop 4.3 4,5 6,6 2.4 2.5
,7 ORF049RIsiING-finger-containingE3ubiquitinligase AAT1876 11,6 3,5 2,3 3.5
s OR[F054RPutative]ptAguanylytrap.sfgr?.se A-AL9878g 1.4 g.s 3.5 2.2 2.2
.9 OR[F063RLargestsubunitofDNA-dependentRNApolymerase BAA82753 4.7 2.5
IIO
JI
ORF077R.
ORIF092R
Pu.tativeDNA-bindingRr9!Fil.l..
.Putatiye.repticationfactor
Mrv1873
AAS18131
4.5
3.7
9.1
15.7
2.9
3.8
2.0
2.0 3.0
.12 ORF097RHypotheticalprotein 5,9 13.1 3.8 2.6'
'13 O]{E..1O1B Hypotheti:.alp;otg.i......... S6 25.4 2.6 2.3 4.1
•14 OR[Fle6RHrny.p..D.theticalprotein 6.2 24.7 3,3 1,8 2.6
l15 OR[F11IRHypotheticalprotgin. 4,9 3o.g 4.6 2,6 3.7
.16 OR[F122RHyp.etheticajprotein 3,2 14.3 3.3 2.0 2.9
'17 OR[E..l.?8R ;.l.mp....oth.etiFalprotF.i........-......nv.. lg,3ttt 4.3 2,3 3.4
ilg ORF135LHypotheticalprotein 3.0 le.6 3,2 2,3 3.3
l19 0RIF140RCytosineDNAmethyltransferase. AAM1861 8.1 2.7 1.3i
2e ORF145RHypotheticalprotein 13.7 3.3
;21 ORIF151RH.ypothetical.prgte.ml..........nv......"
'
10.8 3.2 1,6
l22 O]XF156R[[hioloxidereductase AAP33193 112 3.S 1.7•
,23 ORF161LUYI)Otheticalprotein 14.g 3.1 1.6
'24 ORF162RHypotheticalprotein 10.1 3.2 1.5
25 ORF171B.Hypothetiealmplein.. IS.2 3.3 1.6
26 ORF179LHypothetiealprotein O.8 S.7 2.5 12
27 ORF180RHypotheticalp[otein 16,8 4,8 1,9
28 ORF186RHypotheticalprotein 15,4 3,4 1.7.
29 OI(F197L.
-
g.yp.othgts.'ealprgtFin....
ttt
19.7 4.0 2,4i 3,6
i30 ORF19gRHypotheticalprotein 6.7 3.1 1,3
i31 ORF224LR[NApolymerasebetasubunit. AAT184g 7.6 3.S
32 ORF226RHypotheticalprotein 2,9 2.9 2.7 1.5
,33 ORF237LIprgestsubunitefPNA.-dgpendent.l.31rl.-...ApolymeraF.{... ABO18418 12.1 2.3 l5
134 ORF239RLargestsubunitofDNA-dependentRNApolymerase BAA82753 7,4 3,4 2,2
.35 OR[F256RDNArepairproteptB.AD2. BAA82754 18 9.7 3.6 2.0
i36 ORF26gLRibanucleotidereduetasesmallsubimit BAA82755 11.7 3.5 1.7
37 ORF291Lttin.t. L4rniniIiJ.typg,gp.id,erT;iq.l.growthfacto;;li.k..Fdomai;? AtL[[71838 4.5ttt.tttt.t ..2.?.. 4.6 2.4 3.3
.38 OR[F317LDNApolymerase 070736 1.4 12.2 3.5 1.S
i39 OR[F321RDNApolymerase ,IU3Oe7366 2,1 13.9 2,2 1,O 1,5
'40 ORF324RDNApolymerase ABOD7366 15.6 23.7 2.6 1,5 3,5
,41 OR[F333Ltttt Hy.R..otheticadprotein.
tt
3.1 17,O 3,3 1.6
'42 ORF342LHypotheticalprotein 18,2 2,8 2.0 18
.43 OBF.349LS.erine/thr,egninep;,,o,teinIFinasecatalyticdemaip IL4P.1828 4.4 16,4 3,7 1.g 2.1
I44 OR[F351RHypetheticalprotein 6.5 2.9
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Table 2. Continued
Accession Foldchange
.Ne ORF FutativeFurtction No. 5d.p.i. 7 dp.i.9d.p.i. IO d.p.i.14 d.p,i.
45 ORF353RH.ype!l}gticalRIgtein 2,9 8,5 2.8, 1.9 2.6
/45 ORF37.3mLH.yp...o!l.ie4calprotein 3,3 10.5 3.8 1.9• 3.1
4..1. 9R.Fsu.b...l.?.g.B. Hmhypnvg..l...;..t/..g....al.......p..rgt.g.i... 2..1... 25.0ttt 4.3 1,5
4g o]iaF3goR. l4//pr.capsidprotein BAC66968 4.01 24.6•tttttt 3,6 1,8 2.7
t-tttt
49 ORF385RCatalyt.ig.4omptt.-..uofcti.-likephosphatas.e MP1821 12.2 3.0 15
so ORF390RHypotheticalprotein 3.7 3,5
51 ORF394RHypotheticalprotein 2.8 3.6
52 ORF396RTransmembraneaminoacidtransporter M"1g16 5.3 3.5 15
53 ORF401RHypotheticalprotein 1.8i 11,3 2.8 15
l54 ORF407RAT[Pase ABO07367 3.8' 16.4 3,1 1.7 3.0
,55 O]MF412LA[[[Pase MO16492 1,41 14.8' 3,1. 1,8 1.8
55 ORF413RAEPase ABO07367 18 18,1 3.1' 1,4 2.1
57 ORF420LHypotheticalp.rotein 9.9 4.8i 1.8
•sg OIllF423L RIN'G-fingerdornain-containingproteinttt M"19O6 6.2 2.6 1.4
59 OR[F424RPutativeani[yrinrepeatprotein AAL988O1 15,2 4.2 1,5
'60 ORF426RHypotheticalprotein 4,5 41.0 4S' 25 4.0
l61 OR[F430LPut.al4vg.phg.E.phatase.. A-AM1g37 1,7 23,9 3.5 1,7 2.0
62 ORF458LHypotheticalprotein 2.1 9.3 34 2,3 3.3
I53 ORF463RHypQg.heti.c"ajp;ot.e.i.-."..M.""..M 5.5 4.0
.64 ORF487LProlferatingcellnuclearantigen NP078615 O,8, 12A 2,7• 1.8
65 ORIF488RPutativetmornecrosisfaetorreceptorassociatedfactor AAL9g835 4,4 3.0
66 OR[F493RD5family1>TI[Pase MS18g67 8.8 3.6 15
l67 OR]F502RHyp"othegcalprotein. 5.2 3,2
68 OR]F506RHypotheticalprotein 3.7 3,1
l69 ORF515LHyR.othetieal.protein... so 3.0
I70 ORF534Lasy;1!.l.rg.peqt-cg.n!tll.iajg'"''prQsein Mrv19O9 3,7 3.9, te
ttfitttttt
i71 OR[F535RHypotheticaj..pr.oteig. 6.5, 25.8' 2.4. 2.0 3.1
i72 ORF5434.IllIN- {.}r.lll.}gm,.F;..E.l.glp.tt.nvi.gg.I.1!4i{.ii4g,protein...... Mrv19e6 5D
ttttt
115ttrvtttt 3.4. 2.2 3.3
73 OR[F55aRHypothet/calp.;.g.!.g.ip.nv.- 49 21.5 3.5. 2,4 4.3
'74 ORF554RHypotheticalprotein 1.6 19.0 2.6. 1.4 1.9
75 ORF562RHypotheticaiprotein 2,8• 14.7 2.7 2.1 2.6
i76 ORF569RHypotheticalprotein 12 5.5 2.7
l77 ORF575RHypotheticalpretein O.8 16.5 4,2 1,6
l78 ORF586LHypetheticalprotein 10,9i 3,1•
79 OR[F591RHyr)otheticalprotein 3.9 2,1
lse OR[F596LdsRNA-specficribonuclease AAT1898 O.9• 6,3 3.2.t 1.3
81 OR[F600LHypotheticalpretein 4.8 2.7• 1.1
ig2 OICF606RHypotheticalprotein 6.8i 3.8 1,2
83 ORF617LHypothenicalprotein 9.7 2.6
i84 ORF618RHypotheticalprotein 4.6
l85 O]llF62gL Hypotheticalprotein 1.4 17.3 3.7 2.0 2.2
86 ORF632LHypQtheticalprotein 1.8 18.4 3.6 1,7 2.1
'87 ORF635LHypQthenicalprotein 1.3 19.0 3.8/ 1.7 1.7
i88 OR[F64IL Putativeanlcyrinrepeatprotein ma98801 16.1 4.0 1,7 1,6
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Fig. 2: Hierarchicat ctuster analysis of differentiaily RSIV gene expression between
spleen and kidney. Expression ratios for each ORF were categorized by an average linkage hierarchical
clustering program. Each row represents the expression level ofa single ORF in the spleen when compared
to that in the kidney, and each column indicates time points after infection. The normalized ercpression
levels across all the time points are color-coded. Red boxes indicate up-regulation in expression (median
ratios from 2.0). Black boxes indicate no change in expression (median ratios during O.5 - 2.0), and gray
boxes indicate missing or not detected. The magnitude ofup-regulation is shown by differing intensities of
red, with deep red showing lower expression and bright red showing the highest levels of expression.
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Table 3. Summary ofmicroarray analysis ofdifferential RSIV gene expression between
           spleen and kidney over the time-course of an in vivo infection
Spotted genes 92
Days post infection 5d.p.i. 7d.p.i. 9 d.p.i 10 d.p.i. 14 d.p.i.
Expressed genes 46 88 87 72 44
No. of genes expressed at higher levels in spleen
O/o of genes expressed at higher levels in spleen
 28
60.9
 88
1OO
 87
1OO
 27
37.5
 36
81.8
No. ofgenes expressed at similar levels
O/e of genes exnressed at similar levels
 18
39.1
o
o
o
o
 45
62.5
  8
18.2
 A (23 cycles)
 2dpft 3dp.i. 5dp.i. 7dp.i. 9dpi. 10dpi. 14dp.L
SK SKSKSKSKSKSK IE gene
                                ORF 097R
        '
                                  E gene
                                ORF 618R
                                  L gene
Eil:ISII=RIIX Sl Z:IS:=SllS 6-actin
 B (27 cycles)
 2dpi. 3dp.L 5dp.L 7dp.i, 9dp.L 10dp.i. 14dp.L
SK SKSKSKSKSKSK
Fig. 3: RT-PCR ana!ysis of RSIV transcripts in spleen (S) and kidney (K) of RSIV-
infected red seabream. cDNAs were synthesized from 5 pg total RNA taken from the same samples
used for the microarray experiments. One pl of cDNA was used for 30 pl RT-PCR reaction with cycling
conditions as follows: an initial denaturation at 950C for 2 min, followed by 23 and 27 cycles of
denaturation of95eC for 30 sec, annealing at 550C for 30 sec and elongation at 720C for 1 min, and a final
elongation step at 720C for 5 min. A 23 cycle PCR (Fig. 3A) was used to determine differences in
expression of RSIV transcripts between spleen and kidney at the high level spread stage of the infection
while a 27 cycle PCR (Fig. 3B) was performed to show expression differences at the early and Iate stages
ofthe infection. 6-actin transcript was used as an internal control.
2.3.4 Determination ofthe infectious virat concentration in the spteen and kidney
   RSIV titers were measured to determine the infectious viral concentration in infected
spleens and kidneys. The virus titer of the spleen-derived RSIV stock (RSIVs), as
determined by TCIDso assay, was higher than that of the kidney-derived RSIV stock
(RSIVK) (Table 4).
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Table 4. Determination ofthe infectious viral concentration in the spleen and kidney
Value ofvirus titer
Stock Source of stock Virus titer (TCIDsolml)
RSIVK
RSIVs
Kidney
Spleen
          1o5
2.1 Å} O.34 x lo6
2.4 Discussion
   DNA microarray technology has been successfully used to explore viral gene
expression patterns of mammalian and piscine viruses under different conditions in both
cell culture systems and animal models (Lua et al., 2005; Ye et al., 2001). In our previous
study (Lua et al., 2005), RSIV DNA microarrays were used for rapid analysis of the
RSIV gene transcriptional profile over the time•-course of an in vitro infection in a cell
culture system and for grouping genes into temporal kinetic classes, providing a global
picture of transcription and kinetics of RSIV genes during the replication cycle. In the
present study, the same RSIV DNA microarray was used to characterize the viral gene
expression profiles over the time-course of an in vivo infection in a fish model, providing
a better understanding of the pathogenic mechanisms of RSIV infection at the
transcription level. In addition, a comparison of the RSIV gene expression patterns was
perforrned between viral-infected spleens and kidneys to detect the differential viral gene
expression between different targeted organs of RSIV infection, resulting in the better
understanding of the viral pathogenesis, and to further confirm a susceptible organ to
RSIV infection at the molecular level. This study describes the first use of DNA
microarrays to explore gene expression patterns of a fish marine-pathogenic virus in
aquaculture.
   Spleen and kidney were used in this study because they are potential t4rget sites of
RSIV during infection. High viral loads were observed in both the spleen and kidney by
using real-time PCR (Caipang et al., 2003). Enlarged cells, which are reported as
indicators of piscine iridovirus infections, were also found in the spleen and kidney in
fish infected with RSIV, TGIV, SGIV and grouper sleepy disease iridovirus (GSDIV)
(Chao et al., 2004; Gibson-Kueh et al., 2003; Inouye et al., 1992; Mahardika et al., 2004;
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Qin et al., 2002). In addition, the spleen is suggested to be the target organ for RSIV
diagnosis (Manual of Diagnosis Tests for Aquatic Animals - 2003;
htt ://www.oie.intles lnormes/fmanuallA eO032.htm).
   The time-course experiments have allowed us to monitor the expression ofeach RSIV
ORF through an in vivo infection. The timing of viral transcripts that we observed
(beginning at 5 d.p.i. and peaking at 7-9 d.p.i.) is similar to what has been observed in
previous studies (Nakajima, 1995; Oshima et al., 1998). In an immunoassay of RSIV-
infected red seabream (Nakajima, 1995), the virus was not detected in the spleen at 1 or 3
d.p.i., was moderately detected at 5 d.p.i. and was strongly detected at 7 d.p.i. Using a
PCR assay, PCR products corresponding to a portion of the ribonucleotide reductase
small subunit gene were not amplified from RSIV-infected red seabream at 1 and 2 d.p.i.
but were amplified starting at 5 d.p.i. (Oshima et al., 1998). Similar results were observed
in Taiwan grouper iridovirus (TGIV) infection, which is caused by a piscine iridovirus
classified into the same group with RSIV (Chao et al., 2002). Particles of this virus were
detected in some internal organs of groupers at 4-5 days after intramuscular infection
(Chao et al., 2002). In Singapore grouper iridovirus (SGIV) infection, viral antigens were
detected in virus-infected fish blood at 3 d.p.i. by using a Western blot analysis (Qin et al.,
2002). Taken together, our results suggest that the pathogenic mechanism of RSIV is
similar to that found in other piscine iridoviruses, such as TGIV and SGIV. Although
viral particles were detected at slightly different times in the above studies by using
either traditional viral teclmiques, such as immunoassay, or molecular techniques, such as
PCR, western blot assays or even the DNA microarray technology, piscine iridoviruses
seem to begin to spread at around 4-5 d.p.i. in infected fish.
   Different viral genes reached peak expression levels at different time points. Almost
all Immediately-Early (IE) genes, including ORFs 049R, 097R, 333L, 342L, 396R, 535R,
591R, and 635L, peaked early at 5 d.p.i. and continued to increase throughout the course
ofthe infection (Table 1 & Fig. 1). Similarly, most Early (E) genes, which are thought to
be involved in DNA replication, including ORFs 033R (Cytosine DNA
methyltransferase); 092R (Putative replication factor); 237L and 239R (Largest submit of
DNA-dependent RNA polymerase); 268L (Ribonucleotide reductase small submit); 317L,
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321R and 324R (DNA polymerase); 407R, 412L and 413R (ATPase); 424R and 641L
(Putative ankyrin repeat protein), as well as 433L (Putative phosphatase), peaked in
expression at 5 to 10 d.p.i., indicating preparation for viral DNA replication. Other E
genes (Table 1) peaked at later time points (7 to 10 d.p.i.). In general, Late (L) genes,
which are thought to encode structural proteins and DNA packaging proteins peaked at
later times post-infection (7 to l4 d.p.i.). However, some other L genes, such as ORFs
037R, 042R, 106R, 11IR, 197L, 291L, 374R, MCP, 426R, 458L, 543R, 550R, and 554R
(Table 1), although expressed early, also peaked later or continued to express throughout
the infection. Our results have shown that IE genes and genes involved in viral DNA
replication reached peak levels of expression first, followed by genes encoding structural
and packaging proteins. The in vivo temporal kinetic expression of RSIV genes found
here are consistent with the in vitro findings reported in our previous studies (Lua et al.,
2005). Taken together, as revealed by viral DNA microarrays in both in vitro and in vivo
studies, the transcriptional profiles of RSIV occur into a temporal kinetic manner,
following a common feature ofthe family Iridoviridae in particular, and a classical virus
gene expression cascade ofDNA viruses in general.
   Our finding that the in vivo expression profiles ofRSIV gradually declined in both the
numbers and the expression levels after 10 d.p.i. (Table 1 & Fig. 1) indicates that the
virus was being gradually cleared by host antiviral immune defenses. Similarly, Caipang
et al. (2003) showed with real-time PCR that RSIV was cleared from both the vaccinated
and unvaccinated red seabream after viral challenge, and Chao et al. (2004) showed with
histological, ultrastructural and in situ hybridization that the number of basophilic
enlarged cells (virus-containing cells) gradually decreased from 7 d.p.i. in TGIV-infected
groupers. Chao et al. attributed the viral clearance to either an improved host defense or
to depletion of susceptible cell types (Chao et al., 2004).
   Differences in viral gene expression between different targeted-organs or cell types
enhance a better understanding of pathogenesis of the virus (Cummings and Relman,
2000; Yamagishi et al., 2e03). A comparison of expression profiles of known ORFs in
AcMNPV between two viral-infected cell types clearly provided information on the
replication and pathogenesis ofthe virus in a variety ofhost cell types (Yamagishi et al.,
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2003). Similarly, differential viral gene expression patterns in different targeted organs of
RSIV infection in fish further confirmed the viral pathogenesis. The finding that all RSIV
ORFs were expressed at either higher levels or similar levels in spleens when compared
with those in kidneys throughout the infection indicates that RSIV appears to
preferentially target the spleen. The higher expression of all viral ORFs in the spleens
from 7 to 9 d.p.i., together with over tenfold higher of about 600/o ORFs at day 7 after
infection (Table 2 and Fig. 2)) strongly suggest that the spleen is a susceptible organ for
detection of RSIV disease. Interestingly, IE genes (ORFs 049R, 097R, 333L, 353R,
535R) all expressed early and continued with higher expression levels in the spleens
when compared to those in the kidneys over the time-course of the infection. In addition,
the MCP and some genes that function in nucleotide metabolism or DNA replication
(ORFs 092R, 128R, 324R, 407R, 412L, 413R, 562R) also peaked early and expression
levels remained higher in the spleens than those in the kidneys (Table 2). The higher
virus titer of RSIVs (Table 4) indicated that the infectious viral concentration in the
RSIV-infected spleens was higher than that in the RSIV-infected kidneys. These results
are in line with previous studies demonstrating that the spleen is a most susceptible organ
for RSIV infection (Caipang et al., 2003; Inouye et al., 1992; Wang et al., 2003) as well
as other iridoviral infections in fish (Chao et al., 2004; Huang et al., 2004). The spleen
also appears to be where TGIV begins replicating (Chao et al., 2004), and thus has. been
suggested to be used for early screening ofTGIV. Our results support this conclusion.
   The RT-PCR data (Fig. 3) confirmed the microarray results, showing the higher
expression of selected ORFs in infected spleens when compared to those in infected
kidneys. Differences in expression ofviral ORFs between spleens and kidneys at the high
spread stage of the infection could be observed with only 23 PCR cycles (Fig. 3A). On
the other hand, differences in expression at the early and late stages of the infection were
not detectable after 23 cycles but they were detectable after 27 cycles (Fig. 3B). iimiong
the selected ORFs, the MCP gene was found to be expressed at higher levels in the spleen
than in the kidney over the time-course ofinfection. MCP gene contains highly conserved
domains and codes for the major structural component of viral particles (Schnitzler and
Darai, 1993; Tidona et al., 1998; Williams, 1994; Williams, 1996). The MCP gene has
been used to detect and measure RSIV as well as other iridoviruses (Caipang et al., 2003;
66
Kurita et al., 2002; Tidona et al., 1998). Thus, our results further confirm the hypothesis
that the spleen is the target organ for RSIV infection. Also seen in RT-PCR analysis, IE
genes were also observed early and were expressed throughout the virus infection, and
followed by the expression of E and L genes. Therefore, RT-PCR results confirmed the
microarray data and further confirmed that the transcriptional profiles of RSIV follow a
temporal kinetic cascade.
   In conclusion, the present study provides the first global analysis of RSIV gene
expression patterns in a fish model. Our results show that the pathogenesis of RSIV
spread from 5 d.p.i. and continued with high levels of viral multiplication until viral
clearance by host antiviral defenses starting from around 10 d.p.i. A comparison of viral
gene expression patterns between infected spleens and kidneys provides a better
understanding of the viral pathogenesis, and further confirms, at the molecular level, that
the spleen is a susceptible organ of RSIV infection. This study is the continued analysis
of RSIV gene expression pattems in vivo to complete transcriptional profiles of RSIV
both in cell culture and fish model systems. Such studies would enhance our
understanding of the molecular pathogenic mechanisms of RSIV infection and further
provide a possible clue for selection of the most susceptible organ for detection of
iridoviral diseases iR fish.
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CHAPTER3
INHIBITION OF RED SEABREAM IRIDOVIRUS (RSIV) REPLICATION
BY VIRAL GENE-SPECIFIC siRNAs IN A CELL CULTURE SYSTEM
74
Abstract
   Small interfering RNAs (siRNAs), mediators of a process of sequence-specific gene
silencing called RNA interference, have been shown to have activity against a wide range
ofviruses and are considered to be potential antiviral tools. Here we describe an antiviral
activity of a siRNA that targets the major capsid protein (MCP) gene of red seabream
iridovirus (RSIV), a marine fish-pathogenic virus, in a cell culture system. Inhibition of
RSIV replication was demonstrated by reduced MCP expression level and reduced RSIV
titer. MCP-targeted siRNA (siR-MCP) dose-dependently inhibited the expression of
MCP gene in cells that either transiently expressed or stably expressed the MCP gene. At
84 and 96 hours after viral infection, siR-MCP reduced the expression ofMCP gene by
55.20/o and 97.10/o, respectively. Transfection with siR-MCP reduced the production of
RSIV panicles in supematants of samples infected with RSIV, while the corresponding
mismatched siR-MCP (MsiR-MCP) and nsRNA controls did not exhibit this effect.
These results show that MCP-targeted siRNA can effectively and specifically inhibit the
expression of the target gene and hinder RSIV replication during an in vitro infection,
providing a potential approach for the control ofviral diseases in aquaculture.
Keyvvords: RNA interference (RNAi); small interfering RNA (siRNA); major
        capsid protein; MCP; red seabream iridovirus; RSIV
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3.1 Introduction
   RNA interference (RNAi), mediated by small molecules of double-stranded
(ds)RNAs, is a natural biological mechanism for silencing genes that is widely conserved
in diverse organisms ranging from plants to man, and is shown to have activity against a
wide range of viruses and thus is promising a new antiviral therapy (Andino, 2003;
Coburn and Cullen, 2002; O'Brien, 2007). It is a process of sequeRce-specific gene
silencing in the cytoplasm of eukaryotic cell, in which small interfering RNAs (siRNAs)
of21-23 nucleotides (nt) are associated with a multiprotein complex known as the RNA-
induced silencing complex containing siRNA (siRISC) to target homologous mRNA for
degradation based on complementary base pairing. siRNAs can be processed in cells
from longer double-stranded RNAs produced by viral infection, by transposons or can
also be chemically introduced into cells from the outside (Agami, 2002; Carmichael,
2002). Therefore, introduction of 21-23 nt siRNA duplexes specific for viruses into cells
could lead to viral mRNA degradation and inhibition ofviral gene expression and viral
replication. Recent studies have proven that siRNAs can inhibit replication ofmany kinds
ofviruses at several stages of infection in various cells (Ferreira et al., 2007; Haasnoot
et al., 2003). sjRNAs can be employed to suppress the expression of viral genes in plant
cells (Yelina et al., 2002), insect cells (Adelman et al., 2002; Caplen et al., 2002),
mammalian cells (Capodici et al., 2002; Novina et al., 2002; Surabhi and Gaynor, 2002),
as well as aquatic animal cells (Tirasophon et al., 2005; Xie et al., 2005).
   Efficient inhibition has been demonstrated for DNA viruses both in cell culture
systems and experimental animal models. These include hepatitis B virus (HBV) (Giladi
et al., 2003; Morrissey et al., 2005; Wu et al., 2007), herpes simplex virus l (HSV-l)
(Bhuyan et al., 2004), herpes simplex virus 2 (HSV-2) (Palliser et al., 2006), human
papillomavirus type 18 (HPV-18) (Hall and Alexander, 2003), human cytomegalovirus
(HCMV) (Wiebusch et al., 2004), human herpes virus 6B (HHV-6B) (Yoon et al., 2004),
JC virus (JCV) (Orba et al., 2004), murine herpesvirus 68 (MHV-68) (Jia and Sun, 2003),
anatid herpes virus 1 (AHV-1) (Mallanna et al., 2006), vaccinia virus (Dave et al., 2006),
and tiger frog iridovirus (TFV) (Xie et al., 2005). II]he results ofthese studies suggest the
possibility of using siRNAs as an antiviral tool against DNA viruses.
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   Red seabream iridovirus (RSIV), a fish-pathogenic virus, causes a systemic infectious
iridoviral disease known as red seabream iridoviral disease (RSIVD) in cultured marine
fish in some parts of the world (Do et al., 2004; Inouye et al., 1992; Kawakami and
Nakajima, 2002; Wang et al., 2003). Therefore, it is necessary to develop novel
therapeutic approaches that effectively inhibit RSIV replication. RSIV is a double-
stranded DNA virus with the genome encoding a major capsid protein (MCP) gene and
92 other putative open reading frames (ORFs) (Kurita et al., 2002). The MCP gene
accounts for about 450/o ofthe total protein ofthe virus and is needed for the cleavage and
packaging of viral DNA to form viable virions (Williams, 1996). This gene has been
selected to analyze the phylogenetic relationships ofiridoviruses (Go et al., 2006; Imajoh
et al., 2007; Lu et al., 2005) and has been confirmed to be the most suitable gene for
detection arid measurement ofRSIV infection in previous studies (Caipang et al., 2003;
Dang Thi et al., 2007), and in this study (chapter 2).
   In the present study, we have utilized the MCP gene ofRSIV as a target for siRNAs
in order to determine whether viral gene-specific siRNAs can be used as an antiviral tool
against aquatic iridoviral infections. MCP-specific siRNA was tested for the inhibition of
RSIV replication in a cell culture system. siRNA is a sequence-specific gene silencing
mechanism, and inhibits the target gene in a dose-dependent manner (Colbere-Garapin et
al., 2005; Elbashir et al., 2001; Huelsmann et al., 2006; Zheng et al., 2005). Therefore,
siRNA was initially assessed for inhibitory effects on the MCP gene silencing in cells
either transiently or stably expressing the MCP gene by using a plasmid expressing the
target gene, and it was then tested for its inhibitory effect on RSIV replication in terms of
MCP gene expression during viral infection and in terms ofreduction in viral production.
Our data provide evidence that siRNA can be used to selectively block viral gene
expression and hence viral replication in fish cell lines.
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3.2 Materialsandmethods
3. 2. 1 Cell eutture and virus
   Grunt Fin (GF) cells (Clem et al., 1961) and Hirame Natural Embryo (HINAE) cells
(Kasai and Yoshimizu, 2001) were maintained following Lua et al. (Lua et al., 2005). GF
cells were used for propagation of virus stock while HINAE cells were used for
transfection experiments.
   RSIV was obtained from a spleen homogenate of RSIV-infected red seabream, and
was propagated in GF cells following Lua et al. (2005). The virus titer was determined
using the 500/o tissue culture infective dose (TCIDso) method (Reed and Muench, 1938),
and the virus stock was stored in 1 ml aliquots at -800C until use.
3. 2. 2 Des ign and synth es is ofsiRNAs
   Three (3) duplex siRNAs were chemically synthesized for use in this study (Table 1).
Among them, a siRNA (referred to as siR-MCP) targeting the MCP gene of RSIV was
designed using the siRNA target finder programme of Ambion
(!tl!!p!!((wyEy,alub!gu,s2gu!Itt11 b ml t tfinder).TwoothersiRNAs(referredtoasMsiR-
MCP and nsRNA) were designed for use as controls of siRNA sequence specificity.
MsiR-MCP was the corresponding mismatched siRNA of siR-MCP and was designed in
accordance with previously published rules (Schyth et al., 2006). nsRNA was identical to
the sequence ofa siRNA (Sil) specific forMCP ofTFV (Xie et al., 2005).
            Table 1. siRNA sequences (sense strand) used in this study
siRNA name Target sequence (5' - 3') Position in gene Source
siR-MCP AACAGACUGGCCAUGCUAAUU164 -182 RSIV
MsiR-MCP AGCAGACUGACUACGCUAGUU
nsRNA CGCCUGGUUGGUACUCAAGUU237-255 TFV
a The corresponding mismatched siRNA of siR-MCP. Mismatched nucleotides are bold and underlined.
b The identical sequence ofsiRNA (Si1) targeting MCP oftiger frog iridovirus (TFV) (Xie et al., 2005)
                                   78
3.2.3 Construction ofMCP-expressingplasmid ipCMTV-MCP) andselection ofstably
     MCP-expressing HINAE transformant
  The fu11 length of MCP was amplified from the RSIV genome with primers
containing EcoRI and l\bal sites (Table 2) by PCR. The PCR products were purified, and
cloned into EcoRI and Xbal sites of pCI-neo mammalian expression vector (Promega,
USA) (Fig. IA). The MCP-expressing plasmid (pCMV-MCP) was extracted and purified
using a NucleoSpin plasmid quickpure kit (Macherey-Nagel, USA) according to the
manufacturer's protocol.
                  Table 2. Primers used in this study
Primer name Primer sequence PCR product
 size (bp)
pCMV-MCP-F
pCMV-MCP-R
5'-ATGAATTCATGTCTGCGATCTCAGGTGC-3'
5'-GCTCTAGATTACAGGATAGGGAAGCCTG-3'
Full length
MCP (L)-F
MCP (L)-R
5'-CCCTATCAAAACAGACTGGC-3'
5'-TCATTGTACGGCAGAGACAC-3'
429
MCP (S) -F
MCP(S)-R
5'-CTGCGTGTTAAGATCCCCTCCA-3'
5'•-GACACCGACACCTCCTCAACTA-3'
100
P-actin (L) - F
P-actin (L) - R
5'-TTTCCCTCCATTGTTGGTCG-3'
5'-GCGACTCTCAGCTCGTTGTA-3'
200
B-actin (S) - F
P-actin (S) - R
5'-TGATGAAGCCCAGAGCAAGA-3'
5'-CTCCATGTCATCCCAGTTGGT-3'
1OO
Restriction enzyme sequences are bold and underlined
  To generate cells stably expressing the MCP gene, HINAE cells were transfected
with pCMV-MCP and cultured with selective medium (Leibovitz's L-15 medium
supplemented with geneticin) (Gibco-BRL, USA) following the manufacturer's protocol.
The presence of a selectable marker, the neomycin phosphotransferase gene, allowed
selecting HINAE transformants that harbored pCMV-MCP under selective conditions.
Normal HINAE cells were sensitive while stably MCP-expressing HINAE transforrnants
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were stable with geneticin. One month post-transfection, the transformants were checked
for the expression ofthe MCP gene (Fig. IB) and used to assess the inhibitory effect of
siR-MCP on the MCP gene in the case ofstable expression.
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Fig. 1. Expression of MCP gene in HINAE transformants. (A) construction of pCMV-MCP.
The full-length of the MCP gene was amplified from the RSIV genome by using specific primers
containing EcoRI and Xbal enzyme sequences and then cloned into pCI-neo expression vector. (B)
Expression of MCP gene in HINAE transformants determined by RT-PCR. pCMV-MCP was transfected
into HINAE cells and transfected cells were cultured under selective medium to select HINAE
transformants. About one month post-transfection, tota1 RNA was extracted from the transformants and
reverse transcribed to cDNA for RT-PCR.
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3.2.4 TransfeetionofplasmidDNAandsiRNA
   HINAE cells were seeded into 24-well or 96-well cell culture plates for about 24
hours (900/o-95e/o confluent monolayer) using L-15 medium containing 150/o of fetal
bovine serum (FBS) (JRH Biosciences, USA) without phenol red or antibiotics prior to
transfection. Cells were transfected following the manufacturer's protocol with
lipofectarnine 2000 (Invitrogen, USA). Opti-MEM I Reduced Serum Medium (Invitrogen,
USA) was used to dilute lipofectamine 2000, plasmid DNA and siRNAs.
3.2.5 Determination of dose-dependent inhibitory effect ofsiR-MCP on MCP gene
      expression by using MCP-expressingptasmid ipCMV-MCP)
   In the case oftransient expression (Fig. 2A), normal HINAE cells were co-transfected
with pCMV-MCP and siR-MCP at final concentrations of30 nM, 60 nM and 120 nM.
Cells transfected with only pCMV-MCP were used as a positive control while un-
transfected cells were used as a negative control. Six hours after transfection, the
transfection complexes were replaced by fresh L-15 medium containing 150/o FBS
without phenol red or antibiotics. At 2 days post-transfection (d.p.t.), total RNA was
extracted from both transfected and un-transfected cells with TRIzol (Invitrogen, USA)
according to the manufacturer's protocol for reverse-transcription (RT)-PCR and real-
time PCR analysis.
   In the case of stable expression (Fig. 2B), HINAE transformants that stably expressed
the MCP gene were transfected with siR-MCP at final concentrations of 30 nM, 60 nM
and 120 nM and total RNA was extracted from both siR-MCP-transfected and un-
transfected HINAE transformants with TRIzol (Invitrogen, USA) at 1, 2 and 3 d.p.t. for
RT-PCR and real-time PCR analysis.
3.2.6 Assessment of inhibitoiy effect of siR-MCP on RSIV reptication in terms of
      MCP gene expression
   HINAE cells were transfected with siR-MCP (120'nM) or un-transfected for 6 hours
prior to infection with RSIV at a multiplicity of infection (m.o.i) of 3 (Fig. 2C). After
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allowing 90 min for absorption, unattached viruses were removed and infected cells were
continuously cultured with L-15 medium supplemented with 150/o FBS, 100 IUIml of
penicillin and 100 pglml of streptomycin. At intervals up to 96 hours post-infection
(h.p.i.), total RNA was isolated from both siR-MCP-transfected and un-transfected
(control) samples with TRIzol (Invitrogen, USA) and subjected to DNase I treatment
(Promega, USA) according to the manufacturer's protocol for RT-PCR and real-time
PCR analysis.
3.2. 7 Assessment ofreduction in viralproduction by siR-MCP
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Fig. 2. Experimental scheme of siRNA-mediated RNAi Transient
expression ofMCP gene by using MCP-expressing plasmid; (B) Stable expression ofMCP gene by using
MCP-expressing plasmid; (C) Expression ofMCP gene under siRNA transfection and RSIV infection; and
(D) Sampling for TCIDso assay. (d.p.t.) days post-transfection; (h.p.t.) hours post-transfection; and (h.p.i.)
hours post-infection.
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   HINAE cells transfected with siR-MCP (120 nM) and un-transfected cells were
incubated for 6 hours prior to infection with RSIV at a m.o.i. of 5 (Fig. 2D). After
allowing 90 min for absorption, unattached viruses were removed and infected cells were
continuously cultured with L-15 medium supplemented with 150/o FBS, 100 IUIml of
penicillin and 100 pglml of streptomycin. Viral supernatants were collected from
transfected and un-transfected (control) samples at 72, 96, and 120 h.p.i. The
supernatants were diluted from 10-i to 10-iO and used to infect HINAE cells with 8
repetitions per dilution to perforrn the TCIDso assay. Virus titers were calculated
following the standard method (Reed and Muench, 1938).
3.2.8 Assessmentoftarget-specii7eityofsiR-MCP
   To examine the specificity of siR-MCP, HINAE cells were transfected with either
MsiR-MCP control or nsRNA control for 6 hours prior to infection with RSIV.
Supernatants were collected at 72, 96 and 120 h.p.i. and assayed for virus titers by using
the TCIDso assay in the same way as for the target siR-MCP (section 2.7).
3.2.9 Reverse-transcri tion (RT)-PCR
   Twenty microlitres (20 ptl) of cDNA was synthesized from 5 pg ofthe purified total
RNA using M-MLV reverse transcriptase (Invitrogen, USA) according to the
manufacturer's protocol. One microliter (1 pl) of cDNA was used for RT-PCR in a
volume of 30 pl. Cycling parameters consisted of an initial denaturation at 95oC for 2
min, followed by 23-27 cycles ofdenaturation at 95oC for 30 sec, annealing at 55oC for
30 sec and elongation at 72oC for 1 min, and a final elongation step at 72oC for 5 min.
The primers used for RT-PCR are shown in Table 2.
3.2.10 euantitative real-time PCR
   Standard curves for quantification in real-time PCR were prepared following Caipang
et al. (2003) using purified PCR products of a 429-bp fragment of the target gene (MCP
gene) and a 200-bp fragment of an endogenous reference (6-actin gene) as standard
templates. Approximately 100-bp fragments of the MCP and B-actin genes in unlmown
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samples were amplified by nested primers (Table 2). The calculation of threshold cycle
(CT) and deterrnination of copy number of the target gene were performed using the
software ofthe 7300 real-time PCR system (Applied Biosystems).
   For the real-time PCR assay, each cDNA was synthesized in a 20 pl reaction mixture
containing 5 pg oftotal RNA as described in the RT-PCR section, and was then brought
up to a final volume of200 pl with sterilized water. Three microlitres of diluted cDNA
was amplified in a 20 pl real-time PCR reaction volume containing 1O pl ofSYBR green
PCR master mix (Applied Biosystems) and primers at final concentrations of O.5 pM.
The real-time PCR reaction was performed in 7300 real-time PCR system (Applied
Biosystems) according to the manufacturer's protocol. Following a denaturation step at
950C for 1O min, 40 cycles of amplification were performed at 950C for 15 sec and 600C
for 1 min. A dissociation stage was also added to detect non-specific products and to
optimize primer concentrations. Each sample was run in quadruplicate.
3.2.11 Data analysis
   Data provided by the 7300 real-time PCR system were normalized according to the
comparative threshold cycle (2'AACT) method (Livak and Schmittgen, 2001). Using the 2-
AACT method, a convenient and accurate method to analyze relative changes in gene
expression between a treatment group and an untreated control from real-time,
quantitative PCR experiments, the data were presented as the Fold Change (FC = 2'A"CT)
in target gene expression (MCP gene) normalized to an endogenous reference gene (B-
actin gene) and relative to the positive control. Finally, inhibition percentages were
calculated as follows:
   Inhibition (O/o) = {1 - (2-AACT oftested sample12'AACT ofcontrol sample)}* 1OO
                                                                '
   All statistical analyses comparing samples un-transfected and transfected with
siRNAs were performed by a paired t-test.
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3.3 Results and discussion
3.3.1 Dose-dependent inhibitory effect of siR-MCP on MCP
HINAE cetls transiently expressing the MCP gene
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Fig. 3. Dose-dependent inhibitory effect of siR-MCP on the MCP gene in the case of
translent expresslon. (A) RT-PCR analysis ofMCP gene expression. HINAE ceils were un-transfected
or co-transfected with pCMV-MCP and siR-MCP at different concentrations. Total RNA was extracted at 2
d.p.t. for RT-PCR. (+) pCMV-MCP transfection, and (-) un-transfected samples. (B) Real-time PCR and 2-
AACT analysis ofrelative expression level of the MCP gene. cDNAs were synthesized from 2 d.p.t. RNAs in
the same way as for RT-PCR, but were brought up to a final volume of 200 pl with sterile water. Mean
values (bars) ofthree independent experiments plus stand deviation (S.D.) are shown. Fold change (FC = 2'
""CT); (30 nM; 60 nM; and 120 nM) siR-MCP concentration; C(+) positive control; (+)p > O.05; ("")p <
O.O1 when compared to the control.
   Two days after co-transfection of HINAE cells with pCMV-MCP and different
concentrations of siR-MCP, MCP gene expression was effectively reduced by siR-MCP
at a final concentration of 120 nM as determined by RT-PCR (Fig. 3A). The real-time
PCR data analyzed by the 2'A"CTmethod indicated that expression of the MCP gene were
reduced by 3.850/o (FC == O.9615 Å} O.044,p > O.05), 45.950/o (FC = O.5415 Å} O.06,p <
O.Ol) and 79.550/o (FC = O.2045 Å} O.028,p < O.Ol) in cells transfected with siR-MCP at
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30 nM, 60 nM and 120 nM, respectively (Fig. 3B). Thus, siR-MCP dose-dependently
inhibits MCP gene expression and is highly effective at a final concentration of 120 nM.
3.3.2 Dose-dependent inhibitory effect of siR-MCP on
HINAE celts stably expressing the MCP gene
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Fig. 4. Dose-dependent inhibitory effect of siR-MCP on the MCP gene in the case of
stable expression. (A) RT-PCR analysis of MCP gene expression. HINAE transformants that stably
expressed MCP gene were not transfected or transfected with siR-MCP at final concentrations of30 nM, 60
nM and 120 nM. Total RNA was extracted at 1, 2 and 3 d.p.t. and reverse transcribed to cDNA for RT-PCR.
(+) un-transfected transformants. (B) Real-time PCR and 2'""CT analysis of relative expression level of
MCP gene. cDNAs were synthesized from total RNAs in the same way as for RT-PCR, but were brought
up to a final volume of200 pt1 with sterilized water. Mean values (bars) ofthree independent experiments
plus S.D. are shown. Fold change (FC = 2-""CT); (+)p > O.05; (')p s O.05; ("")p < O.O1 when compared to
the control
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   siRNAs were also documented silencing of stably expressed target genes (Cao et al.,
2004; Takada et al., 2005). Accordingly, we tested the inhibition ability of siR-MCP in
HINAE transformants that stably express MCP gene. As shown by RT-PCR, MCP gene
expression was not different between un-transfected HINAE transformants and siR-
MCP-transfected HINAE transformants at day 1 after transfection at any of the siR-MCP
concentrations tested. However, a decline in the silencing of MCP gene was observed at
day 2 and day 3 after transfection with 120 nM siR-MCP (Fig. 4A). At 120 nM siR-MCP,
as determined by real-time PCR and the 2-AACT analysis, the decrease after 1 day was only
8.840/o (FC = O.9116 Å} O.14, p > O.05), but after 2 and 3 days, the decreases were
significant (50.740/o (FC = O.4926 Å} O.182,p < O.Ol) and 39.690/o (FC = O.6031 Å} O.057,p
< O.05), respectively) (Fig. 4B). These results confirm that siR-MCP dose-dependently
suppresses the expression of MCP gene and effectively suppresses expression at a final
concentration of 120 nM. As a result, siR-MCP was used at a cencentration of 120 nM in
the following experiments.
3.3.3 InhibitionofRSIVreptieationbysiR-MCP
   The inhibitory effect of siR-MCP (120 nM) was assessed on RSIV replication in
terms of MCP gene expression in HINAE cells over the time-course of viral infection.
siR-MCP effectively reduced RSIV replication with time, as shown by RT - PCR (Fig.
5A). The real-time PCR data analyzied by the 2'AACT method indicated that the
suppression was reduced by 13.040/o (FC = O.8696 Å} O.161, p > O.05), 55.160/o (FC =
O.4484 Å} O.113,p < O.Ol) and 97.140/o (FC = O.0286 Å} O.142,p < O.OOI) at 72, 84 and 96
h.p.i. in siR-MCP-transfected samples, respectively (Fig. 5B). These results show that
siR-MCP inhibits RSIV replication by silencing the expression of the MCP gene.
3.3.4 ReductioninproductionofRSIVpartictesbysiR-MCP
   Major capsid proteins are involved in the assembly of viral particles (Tan and Yin,
2004; Williams, 1996), and a reduction in the MCP expression levels correlates with a
reduction in production of infectious new particles (Radhakrishnan et al., 2004; Xie et al.,
2005). Therefore, siR-MCP-transfected cells were infected with RSIV and cell
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Fig. 5. Suppression of RSIV replication in temis of MCP gene expression by siR-MCP
(120 nM). (A) RT-PCR analysis of MCP gene expression. HINAE cells were not transfected or
transfected with 120 nM siR-MCP for 6 hours prior to infection with RSIV (m.o.i. of 3). Total RNA was
extracted at 48, 60, 72, 84 and 96 h.p.i and reverse transcribed to cDNA for RT-PCR. (C) RSIV infection;
(siR-MCP) siR-MCP transfection and RSIV infection. (B) Real--time PCR and 2-""CT analysis of relative
expression level ofMCP gene. cDNAs were synthesized from time-course RNA samples in the same as for
RT-PCR, but were brought up to a final volume of200 pl with sterilized water. Mean values (bars) ofthree
independent experiments plus S.D. are shown. Fold change (FC = 2-itaCT); (+)p > O.05; ("")p < O.O1; (*"')
p < O.OO 1 when compared to the control.
88
  8.5 -
ANE 7.5 -
xo
es 6.5
5
e5.5
ts
F"'4.5
g3.5
s
  2.5 -
   1.5
-e-- RSrv
- RSIV+s R-MCP
e7Ar-•RSIV+MsR-MCP
-RSIV-nsRNA
    Hours psst-infection (h.pi)
Fig. 6. Reduction in viral production by siRNAs (120 nM) at different time-intervals after
RSIV infection (m.o.i. of 5). siRNA-transfected cells were infected with RSIV at 6 h.p.t. Supernatants
were collected at 72, 96 and 120 h.p.i. and assayed for virus titration. The data show the average titers of
two independent experiments at three time intervals in logioTCIDso plus S.D.
   In TCIDso assays, the average titers of culture medium of siR-MCP-transfected
samples were about 23.7-fold, 86.6-fold and 48.7-fold lower than those of the un-
transfected controls at 72, 96 and 120 h.p.i., respectively (Fig. 6). siR-MCP treatment
clearly showed a dramatic effect on MCP mRNA (Fig. 5A and 5B) but not very clearly
on the production ofvirus particles (Fig. 6). This result may be influenced by differences
in amounts ofvirus inoculums. The siR-MCP-transfected cells were infected with RSIV
at m.o.i of 3 in case of assessment of viral replication, whereas the transfected cells were
infected with the virus at m.o.i of 5 in case of assessment of production of virus particles.
Because viruses replicate naturally in infected cells, therefore, high doses of virus may
enhance fast production of virus particles, interfere in the inhibitory effect of the siR-
MCP, resulting in difficulty in the detection of changes under the siRNA treatment.
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However, this hypothesis needs to be confirrned further. Taken together, although a
dramatic effect on the production of vir'us particles under the siRNA treatment could not
be seen, a reduction in virus particles was determined in siR-MCP-transfected samples
when compared to un-transfected samples (Fig. 6), clearly indicating that siR-MCP has
anti-RSIV activity.
   As also shown in Fig 6, titers in control samples transfected with MsiR-MCP were
decreased only about 1.8-fold, 3.7-fold and 2.1-fold at 72, 96 and 120 h.p.i., respectively
and titers in control samples transfected with nsRNA were similar, and decreased 1 .8-fold
and 2.4-fold, respectively. These results indicate that siR-MCP specifically targets RSIV.
3.4 Generaldiscussionandconclusion
   Viral infection is a severe public health problem with significant personal, social, and
economical consequences. More effective approaches are needed to prevent and treat
viral infection. The exploitations of the RNAi pathway that RNAi is a sequence-specific
gene silencing process through the action of siRNAs and can be induced in cultured cells
by introducing synthetic siRNAs pave a new way for the use of RNAi as antiviral
approaches. This potential use has been comprehensively discussed in numerous reviews
(Andino, 2003; Tan and Yin, 2004; van Rij and Andino, 2006; Wang et al., 2006).
Highly effective inhibition of virus replication by RNAi has been achieved both in vitro
and in vivo. In comparison with other conventional drugs, the inhibition of viral
replication by siRNA molecules has some advantages. The most advantage is that
siRNAs are much easier and more flexible to select target sites because target mRNA and
siRNA are sequence-specific and complementary (Tan and Yin, 2004). siRNAs can
suppress viral replication at several stages of infection, including the very early stages,
when viruses are most vulnerable. More importantly, virus infection not only be
prevented by re-treatment or co-treatment with siRNAs (reviewed by Andino, 2003), but
also be prevented in cells already infected with viruses (Orba et al., 2004).
   Although assembly ofviral particles varies with different virus families, many capsid
proteins are involved in the formation ofvirus particles. Genes code for proteins needed
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for the cleavage and packaging of virus particles are commonly selected as targets for
silencing in siRNA studies of DNA viruses. For instance, siRNAs targeting UL-6 gene, a
structural gene, were applied to AHV-1 (Mallanna et al., 2006), while siRNAs targeting
MCP gene were applied to TFV (Xie et al., 2005). Taken this fact, the MCP gene of
RSIV was targeted for siRNAs in this study, and eur data demonstrated that siRNA
specific for MCP gene efficiently inhibited RSIV replication in terms of MCP gene
expression, and hindered viral production in a cell culture system, and further indicated
that the MCP gene is essential for life cycles ofRSIV.
   Several kinds of controls, such as non-specific siRNAs and mismatched or scrambled
siRNAs, have been used to measure the target specificity in antiviral siRNAs. Non-
specific siRNA controls have been used against housekeeping genes such as
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Kapadia et al., 2003) and
reporter genes such as green fluorescent protein (GFP). However, these controls do not
fu11y demonstrate the specificity of the siRNAs used in these studies because their
sequences are so different from those of the siRNAs (Schyth et al., 2006). Therefore,
mismatched or scrambled siRNA controls that differ from the active siRNA by about 1-4
nucleotides have frequently been used (Kapadia et al., 2003; Schyth et al., 2006; Xie et
al., 2005). The controls used in the present study were MsiR-MCP, a mismatched siRNA
of siR-MCP and nsRNA, an identical sequence of Sil specific for MCP of TFV (Xie et
al., 2005), an iridovirus belonging to different genus from that ofRSIV. Neither control
showed any complementariry to any regions of the whole RSIV genome sequence. Our
finding of no differences in virus titers between siRNA control-transfected and un-
transfected samples indicates that the siRNA controls have no antiviral activity. These
results show that siR-MCP participates in sequence-specific gene silencing of siR-MCP
and confirm that it has antiviral activity.
   Taken together, our data demonstrate that siR-MCP efficiently and specifically
inhibited RSIV replication in terms of MCP gene expression and hindered viral
production in a cell culture system. These results suggest that siRNA methodology can be
used to induce gene silencing in fish cell lines, such as HINAE cells. The success of
siRNA in vitro has led to growing interest in in vivo applications of siRNA, leading to a
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revolution in the control of aquatic viruses. Delivering siRNA in vivo to fishlanimal
tissues is complicated and challenging and involves using physical, chemical or
biological approaches (Xie et al., 2006). Because the main goal of in vivo delivery is to
have active and stable siRNAs in the target cells, efficient delivery system of siRNA
molecules is the most challenging issue. Although delivery strategies for siRNAs toward
treatment of aquatic viruses have not been reported yet, siRNAs have been successfu11y
delivered to animal models in organ systems such as liver, spleen, kidney, lung and
pancreas, and even in central nervous system (Kumar et al., 2007; Luo et al., 2005).
Various delivery methods have been used, including hydrodynamic delivery (Behlke,
2006), viral vector-mediated delivery (Barton and Medzhitov, 2002; Morris and Rossi,
2006; Tiscornia et al., 2003), and lipid, antibodies, ligands and peptides-based delivery
(Behlke, 2006; Leung and Whittaker, 2005; Takeshita et al., 2005). Thus, although
further studies for in vivo siRNA delivery are needed, we have shown here, for the first
time, the potential use of siRNAs as an antiviral tool against marine fish-pathogenic
iridoviruses in in vitro. On the other hand, siRNAs will enable new experimental
approaches to analyzing both viral and cellular gene functions in iridovirus-infected cells.
Such studies could provide basic information for control of infectious viral diseases in
aquatlc systems.
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                 CHAPTER4
   ENGINEERED VIRUS-ENCODED pre-microRNA (pre-miRNA)
INDUCES SEQUENCE-SPECIFIC ANTIVIRAL RESPONSE IN ADDITION
TO NON-SPECIFIC IMMUNITY IN A FISH CELL LINE: CONVERGENCE
 OF RNAi-RELATED PATHWAYS AND IFN-RELATED PATHWAYS IN
              ANTIVIRAL RESPONSE
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                                Abstract
    '
   Transfection with synthesized virus-specific small interfering RNAs (siRNAs)
efficiently inhibits viral replication in viral-infected fish cell lines, implying the
involvement of RNA interference (RNAi)-related pathways in the antiviral responses of
fish cells. Here, we demonstrate that plasmid expressing virus-encoded pre-microRNAs
(pre-miRNAs) can also inhibit viral replication through these pathways. By incorporating
sequences encoding miRNAs specific to major capsid protein (MCP) gene of red
seabream iridovirus (RSIV) and a miRNA specific to hirame rhabdovirus (HIRRV)
genome into a murine miR-155 pre-miRNA backbone, we were able to intracellularly
express viral pre-miRNAs (miR-MCPs and miR-HIRRIV) in a fish ceil line. The miR-
MCPs and miR-HIRRV, delivered as pre--miRNA precursors in transfected cells,
inhibited viral replication when these cells were infected with the target virus. AIthough
this may suggest specific interference, inhibitory effect on viral replication was also
observed in cells transfected with a plasmid expressing pre-miRNA targeting P-
galactosidase gene (miR-LacZ) that served as a specificity control. Expression of pre-
miRNAs was found to activate interferon (IFN)-related pathways, correlating with
upregulation of the antiviral IFN-induced Mx protein. The anti-viral effects of viral-
miRNAs observed here were partly the result of the antiviral miRNA-related pathways
and partly the result of the antiviral IFN-related pathways. We propose that engineered
virus-encoded pre-miRNA can engage not only RNAi-related pathways but also IFN-
related pathways to induce potent antiviral responses in fish cells.
KejJM,ords: RNAi; Interferon; IFN; siRNA; miRNA; Major capsid protein; MCP; RSIV;
                                 HIRRV
1OO
4.1 Introduction
   Small RNA molecules engage in sequence-specific interactions that inhibit gene
expression by RNA silencing. This process fu1fils fundamental regulatory roles as well as
antiviral functions, through the actions of smail interfering RNAs (siRNAs) and
microRNAs (miRNAs) involved in RNA interference (RNAi) pathways. The small RNA
molecules are incorporated into an RNA-induced silencing complex (RISC) and serve as
guides for silencing their corresponding target mRNAs based on complementary base-
pairing (Yeung et al., 2005). siRNAs, which are derived by processing oflong double-
stranded RNAs are often of exogenous origin, degrade mRNAs bearing fu11y
complementary sequences, and are currently being extensively evaluated as potential
antiviral tools. In contrast, miRNAs, which are endogenously encoded and derived by
processing of long hairpin RNA precursors, can either cleave mRNAs bearing fu11y
complementary sequences or inhibit translation of mRNAs bearing partially
complementary sequences (Kusenda et al., 2006; Zeng et al., 2003). A single miRNA
can target numerous mRNAs, often in combination with other miRNAs, thus miRNAs
operate highly complex regulatory networks (Kim and Nam, 2006; Nair and Zavolan,
2006). It is believed that miRNAs are essential regulators of various processes, such as
cellular differentiation, proliferation, development, cell death and pathogen-host
interaction (Ambros, 2004; Miska, 2005; Nair and Zavolan, 2006). However, recent
reviews on the role ofmiRNAs concluded that miRNA machinery can also be exploited
for defense against viruses (Browne et al., 2005; Kloosterman and Plasterk, 2006).
   Although miRNAs can function as siRNAs (Doench et al., 2003; Zeng et al., 2003),
virus-encoded siRNAs have been studied for use in antiviral strategies prior to virus-
encoded miRNAs. The antiviral potential of viral-gene specific siRNAs has been
comprehensively discussed in numerous reviews (Dave and Pomerantz, 2003; Pushparaj
and Melendez, 2006; Sanchez-Vargas et al., 2004; Stram and Kuzntzova, 2006; Tan and
Yin, 2004). While the antiviral potential ofviral-gene specific miRNAs has been reported
for several viruses, including human immunodeficiency virus type 1 (HIV-1) (Boden et
al., 2003; Omoto et al., 2004), simian virus 40 (SV 40) (Sullivan et al., 2005), hepatitis
C virus (HCV) (Zhang et al., 2005), and primate foamy virus type l (PFV-1) (Lecellier
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et al., 2005). These studies have invoived the introduction of plasmid-based expression
systems capable of producing endogenous hairpin miRNA precursors targeting viral-
specific genes into cells.
   The use of plasmid-based expression systems is an easy aRd inexpensive way to
generate miRNAs. However, one major drawback is that the expression of long RNA in
some cases has been shown to trigger sequence-nonspecific interferon responses in the
cells, thereby leading to a global inhibition ofmRNA translation and limiting how usefu1
they are (Dykxhoorn et al., 2003; Samuel, 2001). Due to its antiviral nature, a cellular
interferon respoRse should be given special concern in studies of miRNAs targeting
viruses, where reduced viral replication in RNAi-transfected cells is often taken as
indicative ofsuccessfu1 specific interference (Bhuyan et al., 20041 Kapadia et al., 2003).
   We recently synthesized a siRNA specific to the major capsid protein (MCP) gene of
red seabream iridovirus (RSIV) and introduced it into HINAE cells (Dang et al., 2008).
The results demonstrated that RNAi-related pathways are involved in antiviral defenses
and could be evoked by introduction of small RNA molecules into fish cell lines. Herein,
we describe another potential approach for delivering small RNAs, using an expression
system of pre-microRNAs (pre-miRNAs), and investigate whether engineered viral-
encoded miRNAs can exert antiviral activities through antiviral miRNA-related pathways
in a cell culture system. Two marine fish-pathogen viruses, including RSIV and HIRRV
(hirame rhabdovirus), were used as models in our miRNA studies. By incorporating
sequences encoding miRNAs specific to the MCP gene of RSIV (miR-MCPs) and a
miRNA specific to HIRRV genome (miR-HIRRV) into a murine miR-155 pre-miRNA
backbone under control of Pol II promoter, we were able to intracellularly express miR-
MCPs and miR-HIRRV in cells transfected with plasmids capable of expressing pre-
miRNAs (pcDNA-miRs). The anti-RSIV activity ofmiR-MCPs was initially assessed by
measuring MCP gene silencing by employing transient transfection of a plasmid
expressing the target gene (pCMV-MCP). We then investigated the inhibitory effect of
the miR-MCPs on RSIV replication following challenge with RSIV. The inhibitory effect
of miR-HIRRV on HIRRV replication was demonstrated by reduced expression level of
the viral glycoprotein (G) gene and reduced HIRRV titers in plasmid-transfected cells
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over the time-course of HIRRV infection. Our results demonstrate the utility of
expressing viral-encoded miRNAs through a miR-155 precursor stem-loop structure, and
suggest that viral-encoded miRNAs are able to trigger antiviral miRNA-related pathways
in fish cells. However, further analyses revealed that the expression ofpre-miRNAs also
activated IFN-related pathways correlating with upregulation ofthe antiviral IFN-induced
Mx protein, resulting in non-specific antiviral effects. Our findings proposed that
engineered virus-encoded pre-miRNAs not only trigger the antiviral miRNA-related
pathways but also activate the antiviral IFN-related pathways to mount immunity to a
viral pathogen in fish cells.
4.2 Materialsandmethods
4. 2. 1 Cell culture and vir us
   Grunt Fin (GF) cells (Clem et al., 1961) and Hirame Natural Embryo (HINAE) cells
(Kasai and Yoshimizu, 2001) were maintained following Lua et al. (Lua et al., 2005). GF
cells were used for propagation of RSIV stock, while HINAE cells were used for
propagation of HIRRV stock, as well as for plasmid transfection and virus infection
experiments. The virus titers was deterrnined using the 500/o tissue culture infective dose
(TCIDso) method (Reed and Muench, 1938).
4.2.2 Construetion ofptasmid expressing virus-encodedpre-miRNA ipcDNA-miR)
      andptasmid expressing the MCP gene ipCMV-MCP)
   Three (3) pairs of oligonucleotides encoding MCP-specific miRNAs of RSIV
(referred as miR-MCP-1, miR-MCP-2 and miR-MCP-3), and a pair of oligonucleotides
corresponding to HIRRV genome (referred as miR-HIRRV) (Table 1) were designed
using the RNAi Designer (www.invitrogen.com!rnai). Each oligonucleotide pair ("top
strand" and "bottom strand" oligos) was annealed and ligated into the pcDNA 6.2-
GWIEmGFP-miR vector (Block-iT'M PIo II miR RNAi Expression Vector Kits,
Invitrogen, USA) to create plasmids (pcDNA-miR-MCPs and pcDNA-miR-HIRRV)
capable of producing virally encoded pre-miRNAs in plasmid-transfected cells. The
ligation mixture was then transformed into competent E. coli, One Shot TOPIO, cells
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following the manufacturer's protocol. A control expression plasmid (pcDNA-miR-
LacZ) that expresses pre-miRNA targeting the B-galactosidase gene (miR-LacZ) was also
generated using miR-LacZ-positive ds oligos supplied by the kit.
   The MCP-expressing plasmid (pCMV-MCP) constructed in our previous studies
(Dang et al., 2008) was used in co-transfection experiments to express the target MCP
gene.
   Piasmid DNAs were extracted from positive colonies by standard alkaline lysis
(Sambrook and Russell, 2001). All constructs were verified by DNA sequencing using
ABI Prism@ BigDye@ Terminator kit on Applied Biosystems 3130 Genetic Analyzer
(ww.a liedbios stems.co.' ).
4. 2. 3 Transfection ofi17sh cells with ptasmid DNA
   HINAE cells were seeded into 24-well or 96-well cell culture plates using L-15
medium containing i50/o of FBS without antibiotics for about 24 hrs before transfection
at a cell confiuence of approximately 85-900/o. Cells were transfected with plasmid DNA
using Lipofectamine'M 2000 and Opti-MEM I Reduced Serum Medium (Invitrogen,
USA) following the manufacturer's protocol. The transfection mixtures were removed at
6 hours pos"transfection, and transfected cells were maintained for further processing.
4.2.4 Anti-RSIVaetivityofmiR-MCPs
   miR-MCPs were initially tested for sequence-specific silencing on the target MCP
gene by employing transient transfection of a plasmid expressing MCP gene (pCMV-
MCP). HINAE cells were co-transfected with pcDNA-miRs and pCMV-MCP (Fig. IA).
Cells transfected with only pCMV-MCP were used as a positive control while
Lipofectamine'M 2000-transfected and HINAE cells were used as negative controls. At
each indicated time points up to 7 days post-transfection (d.p.t.), total RNA was extracted
with TRIzol@ (Invitrogen, USA) from transfected cells and reverse transcribed to cDNA
using M-MLV reverse transcriptase (Invitrogen, USA) according to manufacturer's
protocol for reverse-transcription (RT)-PCR analysis.
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Table 1. 01igonucleotide sequences encoding viral pre miRNAs
Name Strand Oligo sequence Position in
 genome
miR-MCP-1 Top
          Bottom
TGCTGTAAAGTAGTCTACTCCCATCTGTTTTGGCCACTGACTGACAGATGGGAAGACTACTTTA
CCTGTAAAGTAGTCTTCCCATCTGTCAGTCAGTGGCCAAAACAGATGGGAGTAGACTACTTTAC
68957-68977a
miR-MCP-2
miR-MCP-3
Top
Bottom
Top
Bottom
TGCTGAATTAGCATGGCCAGTCTGTTGTTTTGGCCACTGACTGACAACAGACTCCATGCTAATT
CCTGAATTAGCATGGAGTCTGTTGTCAGTCAGTGGCCAAAACAACAGACTGGCCATGCTAATTC
TGCTGATTACAGTACGGCACACACAAGTTTTGGCCACTGACTGACTTGTGTGTCGTACTGTAAT
CCTGATTACAGTACGACACACAAGTCAGTCAGTGGCCAAAACTTGTGTGTGCCGTACTGTAATC
68075-68095a
69378-69398a
miR-HIRRV Top
          Bottom
TGCTGTCTCTTTGGAGACTTTCTCGTGTTTTGGCCACTGACTGACACGAGAAACTCCAAAGAGA
CCTGTCTCTTTGGAGTTTCTCGTGTCAGTCAGTGGCCAAAACACGAGAAAGTCTCCAAAGAGAC
1821-1841b
Bold and underlined letters represent sense sequences ofengineered miRNAs derived from the target gene; (a) sequence position in RSIV genome; (b) sequence position in
HIRRV genome (NCO05093)
105
   To elucidate antiviral effects of miR-MCPs on RSIV replication, the expression of
MCP gene was monitored in cells transfected with pcDNA-miRs over the time-course of
either the plasmid transfection or the virus infection. RSIV was inoculated in HINAE
cells transfected with pcDNA-miRs or un-transfected at 1, 3, 5 and 7 d.p.t. (Figs. IB and
IC). After allowing 2 hrs for absorption, unattached viruses were removed and infected
cells were continuously cultured with L-15 medium supplemented with 150/o FBS, 100
IU/ml ofpenicillin and 1OO pglml of streptomycin. At indicated time points after plasmid
transfection and virus infection total RNA was isolated from cells with TRIzol@
                          '
(Invitrogen, USA), subjected to DNase I treatment (Promega, USA), and used to
synthesize cDNA for RT-PCR analysis.
4.2.5 Anti-HIRRVactivityofmiR-HIRRV
   HINAE cells were infected with HIRRV at 1 day after transfection with pcDNA-
miRs (Fig. ID). Viral-infected cell debris and cell-free supernatants were collected up to
7 d.p.t. for further processing.
   To assess inhibitory effect of miR-HIRRV on HIRRV replication in terms of gene
silencing, the expression of G gene, an antigen of HIRRV, was monitored in cell debris
and cell-free supernatants of cells transfected with pcDNA-miRs and infected with
HIRRV by RT-PCR assay. At indicated time points, total RNA was extracted from
plasmid-transfected and virus-infected cells and reverse transcribed to cDNA for RT-
PCR analysis.
   To assess inhibitory effect of miR-HIRRV on HIRRV replication in terms of
production of viral particles, monolayer of HINAE cells seeded in 96-well plates was
inoculated with serial 1O-fold dilutions ofcell-free supernataRt samples, and HIRRV titer
values were measured according to TCIDso method (Reed and Muench, 1938).
4. 2. 6 Exp ression of Mx in HINAE cetts transfected with p cDLNA -miRs
                        '
   cDNAs derived from plasmid-transfected samples and control samples at indicated
time points were further used to determine the expression level of Mx gene. We used
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previously published primers designed for the Japanese fiounder Mx (JFMx) protein
cDNA (Ooi et al., 2006) to amplify the Mx transcripts by RT-PCR assay.
   (A) pcMV-McP & pcDNA-miR
       Co-transfection Sampling for RT-PCR
       HINAEcell 1 3 5 7d.p.t.
   (B)
      gCrDanNs?e-cMtiio'lil Rsivinfection samplingferRT-•pcR
          V-l/.-IL-SL--- !/-
      HINAE cell Wh                                 7d•p•t- 2d.p.i.
   (C) pcDNA-miR
      Transfection RSIV Infection Sampling for RT-PCR
          vf/ v-/-v
      HINAE Cell K.,,g 3ikEk;'.,. 3 5 7d'P't'
   (D)gCrDanNsee-cMtiio':i HiRRvinfection SaMPAinndgTfOcriRDT,,'PCR
          Vf! y"!-
      HiNAECeiiN-ebbti..-",.,sigigk$e:L. 3 4 5 6 7d•p•t•
Fig.1. Experimental scheme ofmiRNA studies; (A) MCP gene silencing by miR-MCPs; (B) Anti-
RSIV activity ofmiR-MCPs in virai-infected cells over the time-course oftransfection with pcDNA-miRs;
(C) Anti-RSIV activity of miR-MCPs in cells over the time-course of plasmid transfection and virus
infection; (D) Anti-HIRRV activity of miR-HIRRV; (d.p.t.) days post-transfection; (d.p.i.) days post-
infection.
4. 2. 7 Reverse- transcrip tion (R T) - PCR
   One microliter (1 pl) of cDNA that was synthesized from indicated RNA samples
was used for RT-PCR in a volume of 30 pl to amplify RSIV-MCP, HIRRV-G and Mx
transcripts. The P-actin transcript was used as an internal control. Thermocycler
conditions consisted of an initial denaturation at 950C for 2 min, followed by 20-30
cycles of 950C for 30 sec, 550C for 30 sec and 720C for 1 min, and a final extension at
720C for 5 min. The primer sequences and the size ofPCR products were shown in Table
2.
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  The PCR products were electrophoresed and visualized in a l.OO/o agarose gel stained
with ethidium bromide under UV light. MCP expression values were measured using
ImageJ software (Abramoff et al., 2004) and normalized to the respective B-actin
expression values. Experiments were done in duplicate.
                      Table 2. Primers used for RT-PCR
Primer name Primer sequence PCR product size (bp)
RSIV-MCP-F
RSIV-MCP-R
5'-CCCTATCAAAACAGACTGGC-3'
5'-TCATTGTACGGCAGAGACAC-3'
429
HIRRV-G-F
HIRRV-G-R
5'-TGCCTACCCTGCTGTCATCAG-3'
5'-TCCATGGTTTTCCACAGAAGG-3'
550
JFMx-F
JFMx-R
5'-GCTCTCTGGGTGTGGAGAAG-3'
5'-ACCAGGCTGATGGTTTCTTG-3'
465
B-actin-F
B-actin-R
5'-ACTACCTCATGAAGATCCTG-3'
5'-TTGCTGATCCACATCTGCTG-3'
510
4.3 Results
4.3.1 TransfectionofpcDNA-miRsinHINAEceUs
  When pcDNA-miRs were transfected into HINAE cells, they allowed co-cistronic
expression of pre-miRNAs with EmGFP gene in cells under the control of the Pol II
human CMV promoter. The co-cistronic expression of the pre-miRNAs was monitored
microscopically under a fiuorescence microscope (data not shown) and the predicted
structures of the engineered pre-miRNAs incorporated into the murine miR-155
backbone are shown in Fig. 2.
4.3.2 Anti-HIRRVaetivityofmiR-HIRRV
  Transfection with pcDNA-miR-HIRRV reduced the expression of G gene in both cell
debris and cell-free supernatants of viral-infected cells as compared to the positive
control that were only iRfected with the virus at each indicated tirne points (Fig. 3A).
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free supematants of cells transfected with pcDNA-miR-HIRRV and infected with HIRRV; (d.p.t.) days
post-transfection.
109
   As measured by the TCIDso method, fewer HIRRV particles were detected in cell-
free supernatants of cells transfected with pcDNA-miR-HIRRV expressing miR-HIRRV
(Fig. 3B), corroborating the fact that miR-HIRRV efficiently inhibited the replication of
HIRRV in transfected cells following challenge with the virus. These results seemed to
indicate that the engineered viral-encoded miRNAs worked in a highly specific manner to
trigger only the antiviral potency of miRNA-related pathways.
4.3.3 Anti-RSIV activity ofmiR-MCPs
   wnen cells were co-transfected with pcDNA-miRs and pCMV-MCP, miR-MCPs
were able to significantly silence the expression of the MCP gene when compared to the
control samples that were only transfected with pCMV-MCP at 3, 5 and 7 d.p.t. Although
all three miR-MCPs exhibited the reduction of the target gene expression levels, miR-
LacZ seemed able to slightly reduce the expression ofMCP gene (Figs. 4A and 4B).
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   In the case of transfection with pcRNA-miRs and infection with RSIV, miR-MCPs
inhibited RSIV replication, resulting in reduction of the expression level ofMCP gene in
infected cells. But a similar pattern of antiviral activity was observed with miR-LacZ in
cells transfected with pcDNA-miR-lacZ (Fig. 5A and 5B).
   Taken together, these unexpected results let us to hypothesize that the antiviral effect
observed here were not solely due to the antiviral potency of RNAi-induced miRNAs.
Transfection with plasmids capable of expressing pre-miRNAs could trigger not only the
antiviral potency of RNAi, but also activate other cellular mechanisms that interfere in
antiviral responses in HINAE cells.
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4.3.4 IFNactivationbytheexpressionofpre-miRNAs
   Based on earlier studies, Mx protein is a molecular maker of type I IFN (ctIS)
production in fish (Nygaard et al., 2000; Pakingking et al., 2004) and have antiviral
activity against a wide spectrum of viruses (Ooi et al., 2006). These were confirmed in
our applied setup where stimulation of HINAE cells with dsRNA molecules poly (I:C)
significantly induced the expression of Mx gene, and poly (I:C)-stimulated cells slightly
reduced the expression of MCP gene following challenge with RSIV (Fig. 6). To
examine whether transfection ofHINAE cells with plasmids expressing pre-miRNAs had
any effect on antiviral IFN activity, the expression of Mx gene was investigated in cells
co-transfected with pcDNA-miRs and pCMV-MCP (Fig. 7A), and in cells transfected
with pcDNA-miRs and infected with either RSIV (Fig. 7B) or HIRRV (Fig. 7C), as well
as in cells only transfected with pcDNA-miRs (Fig. 7D).
                             ix
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                            M twts-+xetii}
Fig. 6. Effect of IFN stimulation on RSIV replication. HINAE cells seeded onto 24-well plates
were stimulated with 50 pglml poly (I:C) to induce IFN production. Induced cells and un-induced cells
were infected with RSIV at 6 hrs after stimulation. After allowing 2 hrs for absorption, unattached viruses
were removed and infected cells were continuously cultured with fresh growth medium containing 50
pglml poly (I:C) and further maintained for 72 hrs. The expression of Mx and MCP genes was monitored
by RT-PCR. (1) HINAE cells with stimulation of poly (I:C) and infection of RSIV; (2) HINAE cells
without stimulation but infection ofRSIV.
   As deterrnined by RT-PCR in Fig. 7A, HINAE cells co-transfected with pcDNA-
miRs and pCMV-MCP showed higher expression levels of Mx than the background
expression level observed in cells transfected with pCMV-MCP or Lipofectamine'M 2000
at each of the indicated time points of the transfection. The umegulation of Mx gene was
also observed in plasmid-transfected and viral-infected cells when compared to the
controls that were only infected with viruses (Figs. 7B and 7C). More importantly,
transfection with various pcDNA-miRs differentially induced the expression of Mx gene
(Fig. 7D). These results indicated that the expression of pre-miRNAs was responsible for
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the upregulation of Mx gene, and further suggest that each pre-miRNA exhibited its own
level of expression in the cells, resulting in different expression levels of Mx gene.
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Fig. 7. Induction of the IFN pathway in cells transfected with pcDNA-miRs; (d.p.t.) days
post-transfection; (cyc) cycles of RT-PCR; (A) expression of Mx gene in cells co-transfected with pcDNA-
miRs and pCMV-MCP; (B) expression of Mx gene in cells transfected with pcDNA-miRs and infected
with RSIV; (C) expression of Mx gene in cells transfected with pcDNA-miRs and infected with HIRRV;
(D) expression ofMx gene in cells transfected with pcDNA-miRs; (1) miR-MCP-1; (2) miR-MCP-2; (3)
miR-MCP-3; (4) miR-HIRRV; (5) miR-LacZ; (-) HINAE cells.
4.4 Discussion
   RNAi triggered by small RNA molecules, including siRNAs and miRNAs, offers a
new approach to controlling viral infections. Thus far, viral-specific RNAi has been
generated in a fish cell line by the introduction of synthetic viral gene-specific siRNA in
our previous study (Dang et al., 2008), and by using plasmids capable of intracellular
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expression of virus-encoded pre-miRNAs (pcDNA-miRs) in the present study. In the
previous study, MCP•-targeted siRNA (siR-MCP) effectively and specifically inhibited
the expression ofthe target gene and hindered RSIV replication during an in vitro virus
infection, providing a potential approach for the control of viral diseases in aquaculture.
In the present study, we describe another approach to trigger antiviral RNAi-related
pathways through the action of miRNAs. The present results showed that transfection
with miR-HIRRV silenced the expression level of G gene and reduced HIRRV particles
in infected cells (Fig. 3), and that miR-MCPs inhibited the expression of MCP gene in
cells co-transfected with pCMV-MCP (Fig. 4) as well as in cells infected with RSIV (Fig.
5). Taken together, these results suggest that engineered viral-encoded miRNAs had
antiviral activity, showing inhibitory effects on replication of the target virus. The
engineered viral-encoded pre-miRNAs seemed to work in a highly sequence-specific
manner to evoke the antiviral potential ofmiRNA-related pathways in transfected cells.
   Our finding that virus-encoded miRNAs inhibited replication of the target virus, but
miR-LacZ also had inhibitory effects on viral replication (Figs. 3 and 5) strongly supports
our hypothesis that the antiviral effect observed here was not only due to antiviral RNAi.
Long dsRNA induces a sequence-nonspecific IFN response in many mammalian cells,
leading to a global inhibition of mRNA traRslation (Dykxhoorn et al., 2003). In
vertebrates, dsRNA induce not only gene silencing but also a complex antiviral program
mediated in part by type I IFN, which plays a prominent role during the response to
viruses (Robalino et al., 2007; Smith et al., 2005). In vitro transcribed siRNAs and
hairpin RNAs on DNA vectors appear to induce the antiviral IFN-mediated Jak-Stat
pathway and global upregulation of IFN-stimulated genes (Karpala et al., 2005; Kim et
al., 2004; Schyth et al., 2006; Sledz et al., 2003). For instance, in EPC (Epithelioma
papulosum cyprinid) cells, a fish cell line, in vitTo transcribed siRNAs induced an
antiviral type I IFN response, correlating with the expression ofMx protein (Schyth et
al. , 2006). Mx protein is a well-characterized IFN-induced protein with antiviral activity,
and is considered an indicator of antiviral type I IFN expression (Ooi et al., 2006; Samuel,
2001). Thus, the present results regarding Mx gene expression show that the same
problem was observed in another fish cell line, HINAE cells. The upregulation of Mx
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gene in pcDNA-miRs-transfected cells (Fig. 7) indicates that the intracellular expression
of our engineered pre-miRNAs evoked an antiviral IFN-related response in transfected
cells. Therefore, we propose that the engineered virus-encoded pre-miRNAs not only
trigger the antiviral potency ofRNAi, but also evoke an antiviral IFN-related response in
a fish cell line. This study provides, for the first time, evidence that the expression ofpre-
miRNAs, long hairpin RNAs, induced the antiviral type I IFN-related response,
correlating with the upregulation ofthe Mx gene, in fish cells.
   Taken together, our data suggest that both miRNA-related pathways and antiviral
IFN-related pathways contributed to the observed antiviral effects of virus-encoded
miRNAs. A convergence of RNAi and innate immunity in antiviral response was also
described in shrimp injected with viral sequence-specific dsRNA by Robalino et al.,
(2005). The authors reviewed and proposed a model of antiviral immunity in shrimp by
which viral dsRNA engages both innate immune pathways and an RNAi-like mechanism
to induce potent antiviral responses (Robalino et al., 2005; Robalino et al., 2007).
Therefore, the possibility of activation of both RNAi and IFN-related pathways by pre-
miRNAs must be of great interest to the development of antiviral therapeutics for the
control of diseases because these two pathways interact functionally to mount immunity
to a viral pathogen.
   Our results also revealed that miR-LacZ had stronger inhibitory effect on RSIV
replication (Fig. 5) than on HIRRV replication (Fig. 3). In addition, miR-LacZ showed
stronger inhibitory effect on the expression of MCP gene in transfected cells following
RSIV infection than in cells co-transfected with pCMV-MCP that only expressed the
MCP gene (Fig. 4). Given that miRNA silencing pathways do not require absolute
complement of base-paring with target mRNA, we sought to identify targets of miR-
LacZ and found that ORF 424R (Putative anlcyrin repeat protein) of RSIV genome
contains sequences with partial homology to miR-LacZ sequence. While the'
 sequence of
miR-LacZ is partial homology to the non-coding sequence region between the non-virion
protein gene and the RNA polymerase gene of HIRRV genome (data not shown). ORF
424R is classified as an Early (E) gene that is involved in viral DNA replication and has
positive feedback on the regulation of Late (L) genes, such as MCP gene (Lua et al.,
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2005; Williams, 1996). Taken together, our results suggest that miR-LacZ silenced the
expression of ORF 424R through its partial complementarity with the target, resulting in
signiftcant inhibition of RSIV replication. Overall, miRNAs seem to have broad-
spectrum effects beyond the selective silencing of homologous target genes when
experimentally introduced into cells.
   In conclusion, our results indicate that antiviral RNAi-related pathways can be
triggered by the introduction ofboth siRNAs and miRNAs into a fish cell culture system,
providing a new door for the future development of strategies to control viral diseases in
quaculture. However, the introduction of plasmid-based expression systems capable of
intracellularly producing pre-miRNA precursors activates both antiviral miRNA-related
pathways and antiviral IFN-related pathways, and possibly other cellular signaling
pathways in the vertebrates. Although pre-miRNAs activated an antiviral IFN-related
response as shown by upregulation of IFN-induced Mx protein, it is possible that other
cellular signaling pathways are also activated. Therefore, the results of experiments using
miRNA-related pathways should be interpreted with caution. The side effects elicited by
miRNAs should be given special concern because cellular interferon responses in some
cases cause an unintended stimulation and!or a global inhibition ofmRNA translation.
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          CHAPTER 5
GENERAL CONCLUSION AND PERSPECTIVE
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   Viruses are minute infectious agents which are characterized by a lack ofindependent
metabolism and the inability to replicate outside living host cells. Viruses must utilize the
system of the infected host cells for survival and replication; therefore, they have evolved
many strategies to prevent infected cells from being apoptosis and to evade the innate and
adaptive immune responses oftheir hosts. They would exploit the biosynthesis machinery
of host cells to synthesize various components meanwhile inactivate the innate defense
mechanisms of the host, and even deflect the host RNA silencing machinery to their
advantages. Many viruses encode proteins that specifically against host-cell defenses, or
make tiny miRNAs a particularly efficient tool to turn off the expression of specific genes
(Qi et al., 2006). In deed, several viruses produce a persistent carrier state in the host,
rendering their control quite difficult. Thus, understanding the molecular pathogenic
mechanisms of viral infections is necessary and will be of enomious help towards the
development of antiviral approaches.
   Gene expression represents a unique way of characterizing how cells and organisms
adapt to changes in the external environment (Lettieri, 2006). Therefore, analyses ofgene
expression profiles upon viral infections can both facilitates the annotation of the
molecular pathogenic mechanisms of the virus and further provide clues for control of
diseases. The development ofhigh-quality, commercially available DNA microarrays has
allowed this technology to become a standard tool in molecular virology. With the
advantage of the analysis of thousands of genes at the same time, DNA microarrays have
been used to develop a much deeper insight into the mechanism of pathogenesis at the
molecular level.
   The involvement of biotechnology in the control of viral diseases in aquaculture
includes the development of disease-resistant stock, dietary improvements, nonspecific
immunostimulants, vaccines and currently antiviral RNAi-based approaches. Recently,
the availability of the genome sequences of a range of pathogenic viruses provides the
basis for the development ofnew antiviral therapies (DeFilippis et al., 2003). Antiviral
approaches based on RNAi take advantage of this sequence-specific gene silencing
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mechanism triggered by small dsRNA molecules, including siRNAs and miRNAs. Due
to its high specificity, the simplicity of its design, antiviral RNAi technology has
advanced rapidly, opening the possibility for new novel therapeutic procedures.
Attractive targets using RNAi are either viral genes that are essential for virus replication,
or host genes that are essential for virus entry or that play an essential role in the virus life
cycle (Leung and Whittaker, 2005). Small dsRNA molecules can now be obtained in
various ways allowing for numerous in vitro and in vivo applications. All these are
worthwhile and much research efforts have been done to test their efficiency for disease
control. The antiviral potency ofviral-gene specific siRNAs has been comprehensively
discussed in numerous reviews (Dave and Pomerantz, 2003; Pushparaj and Melendez,
2006; Qi et al., 2006; Sanchez-Vargas et al., 2004; Stram and Kuzntzova, 2006; Tan and
Yin, 2004). siRNAs can inhibit viral replication at several stages of infection, including
the very early stages, when viruses are most vulnerable (Carmichael, 2002). Due to its
sequence-specific gene silencing, viral-gene specific siRNAs are currently evaluated as
promising antiviral tools. It is also reviewed that, although miRNAs are involved in
complex regulatory networks, miRNAs can use as antiviral tools against virus infection.
However, the antiviral potency of viral-specific miRNAs has just been reported for
several viruses.
   Both DNA microarray and RNAi technologies have been widely applied in various
mammalian viruses, it is rather new in aquaculture and has just been tested in few aquatic
viruses in vitro. This study, therefore, was carried out to better understand the pathogenic
mechanisms of viral infections in fish utilizing DNA microarray technology, and to
develop alternative antiviral approaches based on RNAi technology using RSIV as a
model. The transcriptional profile ofRSIV was explored over the time-course ofthe virus
infection in infected spleen of red seabream using viral DNA microarrays containing
almost all RSIV putative ORFs. The microarray data analysis indicates that the
pathogenesis of RSIV infection appears to spread at around day 5 and continued with
high levels of viral multiplication until viral clearance by host antiviral defenses starting
from around 10 d.p.i. In addition, the findings that all viral genes were expressed at
higher or similar levels in the spleens when compared with those in the kidneys
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throughout the virus infection further confirm, at the molecular level, that the spleen is a
suitable organ for diagnosis of iridoviral infectioRs in fish.
   The antiviral potency of RNAi, triggered by siRNAs and miRNAs, was applied to
RSIV in in vitro studies prior to their further application for efficient in vivo studies. The
anti-RSIV activity of virally small RNA molecules was investigated in a cell culture
system by the introduction of a naked synthesized viral-specific siRNA and by using
plasmid-based viral-encoded pre-miRNA expression system.
   A siRNA specific to MCP gene ofRSIV (siR-MCP) was designed and tested for anti-
RSIV activity. Transfection with siR-iMCP efficiently silenced the expression of the
target gene and reduced the production of RSIV particles in supernatants of samples
infected with RSIV, while the corresponding mismatched siR-MCP (MsiR-MCP) and
nsRNA controls did not exhibit this effect. These results show that the introduction of
naked siR-MCP into a fish cell line can effectively and specifically inhibit the expression
of the target gene and hider RSIV replication during an in vitro infection, providing a
potential approach for the control ofviral diseases in aquaculture.
   Anti-RSIV activity of viral-encoded miRNAs was investigated in a fish cell line by
using plasmid-based pre-miRNA expression system. By incorporating sequences
encoding miRNAs specific to the MCP gene ofRSIV into a murine miR-155 pre-miRNA
backbone (miR-MCPs) under control ofPol II promoter, we were able to intracellularly
express miR-MCPs in cells transfected with plasmids capable of expressing pre-miRNAs
(pcDNA-miRs). miR-MCPs reduced the expression ofMCP gene, resulting in inhibition
of RSIV replication. However, expression of miR-MCPs was found to activate the
antiviral IFN-related pathways in transfected cells, correlating with the upregulation of
the antiviral IFN-induced Mx protein. The observed anti-RSIV effects of virus-encoded
miRNAs were partly the result of the antiviral miRNA-related pathways and partly the
result of the antiviral IFN-related pathways. In terrns of the potential use of miRNA-
related pathways for development of antiviral therapeutics, the possibility of activation of
RNAi and IFN-related pathways by pre-miRNAs must be of great interest to the control
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of diseases because these two pathways interact functionally to mount immur}ity to a viral
pathogen.
   Despite DNA microarray technology has been successfu11y applied in the field of
molecular virological research, its enormous poteRtial still faces several challenges. The
biggest challenge in DNA microarrays is the challenge of data handling and informatics
(Choudhuri, 2004). This is due to the large volume ofdata generated in each experiment.
In addition, differential gene expression analysis is not a stand-alone technique; results
must be confirmed through direct examination of selected genes using more sensitive
assays, such as RT-PCR, real-time PCR. A second major limitation is the high cost
associated with the technology itself. These costs render repeat measures very expensive,
and thus often only limited experimental data are available.
   Similarly, the potential for use of RNAi as antiviral tool also has severai limitations
that should be taken into account when designing RNAi-based experiments. Short
dsRNAs (21-23 bp) or siRNAs are commonly used in vertebrates because they are able to
bypass this general non-specific response and achieve gene target-specific silencing via
RNAi. However, one shortcoming of the introduction of naked siRNAs into cells is
transient or short-term effect. To get around this problem, plasmid-based expression
systems for endogenously producing pre-miRNAs have been developed (Tuschl and
Borkhardt, 2002). Although the use ofplasmid-based expression systems is an easy and
inexpensive way to generate miRNAs, the expression oflong hairpin RNA in some cases
have been shown able to trigger sequence-nonspecific interferon responses in the cells,
thereby leading to a global inhibition of mRNA translation (Dykxhoorn et al., 2003;
Samuel, 2001). Thus, caution must be exerted in the interpretation of data from
experiments using miRNA-related pathways. The side effects elicited by miRNAs are of
concern for the use of RNAi technology as antiviral approaches, where gene silencing is
often taken as indicative of successfuI specific-sequence manner.
   Overall, a better understanding ofthe molecular pathogenesis ofRSIV, as revealed by
the DNA microarrays, is enomious contribution to the thorough knowledge of RSIV
infection and control iridoviral diseases in aquaculture. Additionally, in vitro RNAi
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studies have demonstrated that RNAi-related pathways are involved in antiviral defenses
and could be evoked by introduction ofboth viral-specific siRNAs and miRNAs into fish
cells. Thus the antiviral potency of RNAi can be applied in vivo, for instance, by using
transgenic technology. The use of the trangene teclmology will generate transgenic fish
that can induce stable gene silencing, resulting in long-lasting protective potency against
viral infections. However, efficiency and stability of RNAi are influenced by many
factors, including tissue-targeted types, route of administration and delivery vehicles for
generating RNAi. Therefore, in vivo RNAi studies require carefu1 considerations,
especially for the use of delivery system for generating RNAi.
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